

Bannual Meeting of the European Thyroid Association

September 20 - 24, 2008

Thessaloniki-Chalkidiki Greece PORTO CARRAS GRAND RESORT

www.eta2008.gr

Final Program

WELCOME



Dear friends and colleagues,

The General assembly of the 2003 ETA meeting in Edinburgh decided that the 33rd annual meeting of the European Thyroid Association would be held in Thessaloniki, Greece on 20-24 September 2008. It is now exactly 10 years after a similar meeting took place in Athens, Greece under the leadership of Prof. D. Koutras.

Thessaloniki (also called Salonica) is Greece's second largest city, and its cultural capital. It was named in honour of a woman who herself had been named to commemorate a military victory, that of her father, King Philip II, over a tribe in Thessaly with the help of tough Thessalian horsemen. This royal daughter grew up to marry the Macedonian general Kassandros, and later in 316 B.C, he named

the city after her. In 168 B.C., the Romans conquered Macedonia, making it a subordinate province with its capital in Thessaloniki. The city's ideal location on the Thermaic gulf and on the east-west via Egnatia, plus its proximity to the Axios River valley corridor leading north into the Balkans, all helped turn it into a leading commercial center. Under Emperor Galerius in the early 4th century AD, Thessaloniki became the eastern imperial capital, and with the empire's division later that century, it became Byzantium's second city, a flourishing Constantinople in miniature. Ever since the city blossomed culturally and contributed greatly to the Creation of Southeastern Europe and expansion of Orthodox Byzantine literary culture among the Slavs of the Balkans.

In 1430 the Ottomans captured Thessaloniki, under whom it maintained its stature as a major centre of the Ottoman empire. In the late 15th and early 16th centuries, Sephardic Jewish exiles fleeing the Spanish Inquisition transformed Thessaloniki, which would become one of the most important Jewish cities in Europe. Although much of Greece was liberated after the 1821 war of Independence, Thessaloniki and Macedonia remained Ottoman until 1912, when it was liberated by the Greek army, after the "Macedonian Struggle" (1904-1908). Most of Thessaloniki's Jewish population was deported when the city (and the rest of Greece) was occupied during the second world war. (1941-1944). The city was rebuilt with wide avenues designed by a French architect and the population subsequently grew enormously reaching currently the one million mark. Thessaloniki has the largest university in Greece with about 100.000 students. Every September Thessaloniki hosts an International Trade Fair, which is followed by an International cultural festival, which includes film screenings and musical performances. More than half a million visitors are visiting the city during that time.

Thessaloniki has fostered thyroid research for more than 25 years. The "Panagia Hospital" group has made a major contribute to clinical thyroidology. Thyroid eye disease and the effects of thyroid disease on reproduction are the two main topics of research interest of the group. It is noteworthy that the first official satellite symposium meeting of ETA on Graves' orbitopathy was organized by the "Panagia" group in 1998 at Pieria Riviera, which proved to be a great scientific event with more than 200 participants. At the same year the group was selected to be one of the founding member of European Group of Graves' Orbitopathy (EUGOGO), a leading scientific consortium, affiliated to ETA, with the aim of improving research and education on thyroid ophthalmopathy around the globe. In 2005 it hosted the first educational EUGOGO course, attended by colleagues from all over the world and set the standards for subsequent EUGOGO courses. Although financially the group is self-supported, it has been very successful course and has fulfilled its aims better than anyone could have hoped for.

The LOC anonymously decided Porto Carras Grand Resort in Chalkidiki to be the venue of the 33rd ETA meeting. The Porto Carras complex, only 60-90 minutes drive from the "Macedonia"-Thessaloniki airport, was the site of the 2003 European Community Summit. The organization of the meeting in a resort-type venue and not in a university environment or in a convention center, as has been customary in the past, is something that may be characterized as a revolution for ETA standards. Specific logistics needs and financial considerations were the two main arguments in favor of this choice and as our wise predecessors used to say "εκ του αποτελέσματος τα πάντα κρίνονται", which means "judge us by our results"



First and foremost the annual meeting means science. During the last months, the ETA Executive Committee under the leadership of our chairman Josef Köhrle, has prepared an attractive scientific program, which is based on three tracks, i.e. clinical, basic science and educational. Several topic - related symposia, as well as the meet-the-expert sessions will cover current issues of clinical thyroidology, controversies, and basic science. A series of pre-conference and satellite events are linked with this year's 33rd annual meeting: the traditional thyroid ultrasound course, ICCIDD, ETA-CRN meetings and a satellite symposium on somatostatin analogues on Saturday before the opening of the 33rd annual meeting. I'm sure that will attract many attendees. A new component of the scientific program is the organization of three satellite sessions, sponsored by ETA corporate members as early morning sessions with the opportunity to get breakfast on site.

In addition to science the annual meeting offers a lively social program. The welcome reception will take place around the pool of Meliton Hotel and you will have the opportunity to enjoy famous Greek delicacies, accompanied by the delicious "Porto Carras" wine and traditional Greek music. The Gala dinner will take place in a beautiful fish restaurant nearby overlooking a private bay, while for the event you will have the opportunity to sail around the Chalkidiki peninsula with the famous boat "Menia Maria". Dinner, wine, and great music on board all free of charge.

I would like to thank all those who have helped in many different ways throughout the months of preparation for this meeting, especially the secretary of LOC Dr. F. Papadopoulou and the four ladies of Global Events, namely Bessie Palioura, Rania Kallipolitou, Kerasa Mavridou and Anna Gialantzi. Also, the ETA Executive Committee for efficient interaction throughout the preparation of the meeting. After many months of preparations the time has come to pull the curtains. So, welcome to Thessaloniki, welcome to Porto Carras and enjoy the 33rd annual meeting of the ETA.

Gerasimos E. Krassas, MD, PhD, FRCP (Lond) President of the Local Organizing Committee



LIST OF COMMITTEES

ETA EXECUTIVE COMMITTEE

President: **Köhrle J.,** Germany Secretary: **Feldt-Rasmussen U.,** Denmark Treasurer: **Kahaly G.,** Germany

President-Elect: **Laurberg P.,** Denmark Secretary-Elect: **Bartalena L.,** Italy

Members Bakker O., The Netherlands Duntas L., Greece Erdogan M., Turkey Jarzab B., Poland Santoro M., Italy Schlumberger M., France Weetman A.P., UK Williams G., UK

LOCAL ORGANIZING COMMITTEE

Honorary President: Koutras D.

President: Krassas G.E.

Vice Presidents: **Avramidis A., Tsatsoulis A., Vagenakis A.** Secretary: **Papadopoulou F.** Treasurer: **Pontikides N.**

Members: Alevizaki M.	Koukoulis G.	Papapetrou P.
Anastasiou E.	Loustis K.	Pazaitou K.
Efthymiou I.	Mamalaki E.	Tzavara I.
Gogakos A.	Markou K.	Vainas H.
Kaldrimidis Ph.	Mastorakos G.	Vlassopoulou B.
Kaltsas T.	Papadodima E.	

CONFERENCE SECRETARIAT

Global Events

117 Egnatia Str., 54635 Thessaloniki, Greece Tel: +302310 247743, 2310 247734 Fax: +302310 247746 E-mail: info@globalevents.gr www.globalevents.gr



PRECONFERENCE EVENTS

🗖 Saturday, September 20th , 2008 🔳

ICCIDD West Central Europe Regional Satellite Meeting

L	Regional Satellite Meeting		
	08:30-16:00 Olympic Hall		
	08:30-09:00	Registration	
	09:00-09:10	Welcome address Gerasimos Krassas (President Local Organising Committee) Aldo Pinchera (Pisa, Italy)	
		SESSION I SCIENTIFIC SYMPOSIUM Chairmen: Gerald Burrow (Mystic, USA) Aldo Pinchera (Pisa, Italy)	
	09:10-09:25	Salt restriction and cardiovascular disease Pasquale Strazzullo (Naples, Italy)	
	09:25-09:30	Discussion	
	09:30-09:45	USI. Its benefits Peter Laurberg (Aalborg, Denmark)	
	09:45-09:50	Discussion	
	09:50-10:00	Dietary sources of iodine intake and salt as a vector for improvement of iodine status Lars Ovesen (Slagelse, Denmark)	
	10:00-10:15	Discussion	
	10:15-10:20	Pitfalls of iodine overload through excess self supplementation Sergej Hojker (Ljubljana, Slovenia) Discussion	
	10:20-10:40	Coffee Break	
		SESSION II CURRENT IODINE PROPHYLAXIS ISSUES Chairmen: Paolo Vitti (Pisa, Italy) Daniel Glinoer (Brussels, Belgium)	
	10:40-10:55	lodine deficiency in pregnancy – a European strategic problem Zbigniew Szybinski (Krakow, Poland)	
	10:55-11:00	Discussion	
	11:00-11:15	Are thyroid studies comparable? An epidemiological view Henry Volzke (Greifswald, Germany)	
	11:15-11:20	Discussion	
	11:20-11:35	Statement on safety of iodine prophylaxis Paolo Vitti (Pisa, Italy)	
	11:35-11:40	Discussion	



SESSION III

A) UPDATE, IODINE PROPHYLAXIS STATUS IN WEST CENTRAL EUROPE Chairman: **Aldo Pinchera**, West Central Europe Regional Coordinator

- **11:40-13:00 Presentation of new country data by the ICCIDD national representatives**
- 13:00-14:00 Lunch Break

B) UPDATE, IODINE PROPHYLAXIS STATUS IN WEST CENTRAL EUROPE

- 14:00-14:10 ETA Address **Josef Köhrle**, President ETA
- 14:10- 16:00 Continuation of country presentations Discussion and conclusions



ETA-CRN

The 8th meeting of the European Thyroid Association Cancer Research Network (ETA – CRN)

09:30–15:50 | Olympic Hall III

09:30-10:00	Registration & Coffee
10:00-10:10	Welcome & Opening President ETA-CRN, Rossella Elisei (Pisa, Italy) Secretary ETA-CRN, Secretary ETA, Ulla Feldt-Rasmussen (Copenhagen, Denmark)
10:10-12:30	Basic/Translational scientific session Angiogenesis in thyroid cancer Chairpersons: Barbara Jarzab (Gliwice, Poland) Lars Bastholt (Odense, Denmark)
10:10-10:40	Tetrac as a potential chemotherapeutic agent in thyroid cancers Paul J. Davis (Albany, NY, USA)
10:40-11:05	Tyrosine kinase inhibitors for treatment of thyroid carcinoma Massimo Santoro (Naples, Italy)
11:05-11:25	Hypoxia in thyroid cancer Georg Brabant (Birmingham, UK)
11:25-11:45	Coffee Break
11:45-12:10	Translation of mechanism of anti-angiogenic action into clinical use Martin Schlumberger (Paris, France)
12:10-12:30	General Discussion
12:30-13:00	General Assembly - Transition from network to working group of ETA
13:00-14:00	Lunch Break
14:00-15:35	Clinical scientific session Risk assessment of thyroid cancer: Which is the best approach? Chairpersons: Rosella Elisei (Pisa, Italy) Jan Smit (Leiden, The Netherlands)
14:00-14:25	Introduction–different prognostic risk assessments of thyroid cancer Jan Smit (Leiden, The Netherlands)
14:25–14:45	Evidence based use of staging classifications in practice – Is it possible? Catharina Ihre-Lundgren (Stockholm, Sweden)
14:45-15:05	Post-Therapy risk assessment – Is it better? Furio Pacini (Siena, Italy)
15:05-15:35	General Discussion
15:35-15:50	Closing



Practical Diagnostic Thyroid and Parathyroid Ultrasonography Course

08:30-16:00| Meliton Hotel-Erato Hall

08:00–08:30 **Registration**

08:30-09:30 Neck anatomy, basics of ultrasonography and how to perform neck ultrasonography? Murat Erdogan (Ankara, Turkey) Illustrated topographic anatomy of thyroid gland, neck lymph nodes and other structures of the

> neck. Methods of performing US on the neck.

Normal gray scale and Doppler sonography of neck structures. Measurement of antero-posterior, transverse, and longitudinal diameters. Calculation of thyroid and nodule volume (mL) in epidemiology and clinics. General aspects on thyroid echostructure (homogeneity, echogenicity), detection of thyroid lesions (presence of calcifications, cystic lesions).

09:30-10:00 **Gray scale and Doppler sonography in thyroiditis Paolo Vitti** (Pisa, Italy) Gray scale and Doppler ultrasonography findings of different thyroid disorders: (Hashimoto's thyroiditis, Graves' disease, Subacute thyroiditis... etc). Case illustrations.

- 10:00-10:30 Coffee Break
- 10:30-11:15 Ultrasonography in thyroid nodule, FNAB and ultrasonography guidance Theresa Rago (Pisa, Italy) Sonographic definition of thyroid nodule, echographic pattern.

Different gray scale and Doppler parameters of thyroid nodule, echographic pattern. Clinical and sonographic parameters to identify nodules at risk of malignancy. Sensitivity and specificity of different sonographic findings for malignancy (Echogenicity, halo sign, calcification, diameters, Doppler pattern, elastography). When do we need ultrasonography guidance for FNAB? Different practical methods for USG guided biopsy. Case illustrations.

11:15-12:00 Ultrasound guided intervention in nodular thyroid disorders (PLA, PEI, Radiofrequency) Enrico Papini (Albano Laziale, Italy) Indications for therapy, different techniques of percutaneous ethanol injections (PEI). Single or multiple injections, possible side effects, short-term, and long term results.

Principles of percutaneous laser ablation (PLA), therapy apparatous, type of needle, laser source, and technique used.

Selection criteria for thyroid lesions, indications for therapy and possible side effects, short-term, and long term results.

Indications and results in thyroid malignant lesions and distant metastases. Case illustrations (10 minutes).

- 12:00-12:15 Questions and answers
- 12:15-13:30 Lunch Break

13:30-14:00 Parathyroid lesions

Murat Erdogan (Ankara, Turkey) Illustrated topographic anatomy of parathyroid glands and the variations.



21 Saturday 20 Sunday 22 Wedneday 24 Tuesday 23 Monday

Methods of performing parathyroid US on the neck. Gray scale and Doppler US findings of parathyroid disorders. Ethanol ablation and other minimal invasive procedures of parathyroid lesions.

14:00-16:00 Practice on real patients with the lecturers and self practice groups A, B, C, D, E



SCIENTIFIC PROGRAM

Saturday, September 20th, 2008

Olympic Hall I

17:30-19:00 Satellite Symposium Somatostatin analogs: Current and future therapeutic indications Chairpersons: Lewis Braverman (Boston, USA) George Tolis (Athens, Greece)

Somatostatin analogs and thyroid eye disease: where we stand, what we expect in the future Gerasimos E. Krassas (Thessaloniki, Greece)

Thyroid function in humans with morbid obesity. Has somatostatin analogs a role in their treatment? Apostolos Vagenakis (Patra, Greece)

Somatostatin analogs and different neuroendocrine tumours. Special emphasis on medullary thyroid cancer Anna-Maria Colao (Naples, Italy)

19:00-20:00 **Opening Ceremony**

Melliton Hotel, by the pool

20:00-22:30 Welcome Reception



SCIENTIFIC PROGRAM

Sunday, September 21st, 2008

0	lym	pic	Hall	Γ
_				

06:45-07:15 Breakfast (at the Meliton and Sithonia Thalasso & Spa)

07:15-08:30 Satellite Symposium (Genzyme Europe) From guidelines to clinical practice: the practical management of thyroid cancer patients

> Introduction: The objectives of treatment Chairperson: Martin Schlumberger (Paris, France)

The very low-risk patient: the easiest clinical decision? Maria Alevizaki (Athens, Greece)

The low-risk patient: who are they and how should we treat? Markus Luster (Ulm, Germany)

Additional considerations for the high-risk patient Furio Pacini (Siena, Italy)

08:30-10:30
Topic Highlight I
Chairpersons: Josef Köhrle (Berlin, Germany)
Gerasimos E. Krassas (Thessaloniki, Greece)

001 IDENTIFICATION OF NEW GENES INVOLVED IN THYROID DEVELOPMENT AND DIFFERENTIATION

Amendola E.¹, Sanges R.³, De Luca P.², Galvan A.⁵, Terracciano D.⁴, Macchia V.⁴, Dragani T.⁵, De Felice M.⁴, Di Lauro R.¹ ¹Stazione Zoologica A. Dohrn, ²Biogem s.c.a r.l, Ariano Irpino, ³TIGEM, Napoli, ⁴Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita Federico II, Napoli, ⁵Istituto Nazionale dei Tumori, Milano

002 THE MECHANISM OF TRH-INDUCED TRANSACTIVATION OF TSH BETA GENE

Nakamura H., Ohba K., Nagayama K., Matsushita A., Kashiwabara Y., Iwaki H.[,] Matsunaga H., Misawa H., Ishizuka K., Sasaki S. Second Division, Department of Internal Medicine, Hamamatsu University School of

Medicine, Hamamatsu, Shizuoka, Japan

003 A LOW MOLECULAR WEIGHT ANTAGONIST PREVENTS TSH- AND ANTIBODY- INDUCED ACTIVATION OF THE HUMAN THYROTROPIN RECEPTOR

Krause G.¹, Neumann S.², Kleinau G.¹, Costanzi S.², Moore S.², Jiang J.³, Raaka B.M.², Thomas J.C.³, Gershengorn C.M.²

¹Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, ²National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA, ³NIH Chemical Genomics Center, National Human Genome Research Institute, Bethesda, MD, USA

004 VANDETANIB (300 MG) IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER: A PHASE II OPEN-LABEL STUDY

<u>Wells A.S.</u>¹, Gosnell J.², Gagel F.R.³, Moley J.⁴, Pfister D.⁵, Sosa J.A.⁶, Skinner M.A.⁷, Krebs A.D.⁸, Vasselli J.⁹, Schlumberger M.¹⁰

¹Washington University School of Medicine, St Louis, MO, USA, ²University of California at San Francisco, San Francisco, CA, USA, ³UTMD Anderson Cancer Center, Houston, TX, USA, ⁴Washington University



School of Medicine, St Louis, MO, USA, ⁵Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁶Yale University School of Medicine, New Haven, CT, USA, ⁷Childrens Medical Center, Dallas, TX, USA, ⁸AstraZeneca, Wilmington, DE, USA, ⁹AstraZeneca, Wilmington, DE, USA, ¹⁰Institut Gustave Roussy, Villejuif, France

005 EFFECT OF THYROID STATUS ON THE SKELETON IN POST-MENOPAUSAL WOMEN: THE OPUS STUDY

Williams G.R.¹, Murphy E.¹, Glüer C.C.², Reid M.D.³, Felsenberg D.⁴, Roux C.⁵, Eastell R.⁶

¹Molecular Endocrinology Group, Imperial College London, London, UK, ²Universitätsklinikum Schleswig-Holstein, Kiel, Germany, ³Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK, ⁴Free University, Berlin, Germany, ⁵Rene Descartes University, Paris, France, ⁶Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK

006 A LINK BETWEEN X CHROMOSOME INACTIVATION PATTERN AND SUBCLINICAL AUTOIMMUNE THYROID DISEASE. EVIDENCE FROM A TWIN STUDY

Hansen P.S.¹, **Brix T.H.**², Knudsen G.P.S.³, Kringen M.K.³, Kyvik K.O.¹, Sorensen T.H.I.A.⁴, Orstavik K.H.⁵, Hegedüs L.²

¹The Danish Twin Registry, University of Southern Denmark, Odense, Denmark, ²Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark, ³Faculty Division Rikshospitalet, University of Oslo,Oslo, Norway, ⁴Danish Epidemiology Science Centre, Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark, ⁵Department of Medical Genetics, Rikshospitalet University Hospital, Oslo, Norway

Olympic Hall II

10:30-11:00 Coffee Break

Olympic Hall III

11:00-12:30 Symposium 1 (Basic) Oxidative stress. The second aspect of thyroid hormone metabolism Chairpersons: Ralf Paschke (Leipzig, Germany) Maria Alevizaki (Athens, Greece)

> Hydrogen peroxide in thyroid physiology and disease Francoise Miot (Brussels, Belgium)

Thyroid tumours and mutagenesis: a collateral damage? Knut Krohn (Leipzig, Germany)

8-oxo-Guanine and cancer Marcus S. Cooke (Leicester, UK)



Olympic Hall I

11:00-12:30 Symposium 2 (Educational) Ultrasound in thyroidology Chairpersons: Laszlo Hegedus (Odense, Denmark) Dimitrios Linos (Athens, Greece)

> Diagnosing malignancy by ultrasound Paolo Vitti (Pisa, Italy)

Cancer follow-up by ultrasound Laurence Leenhard (Paris, France)

Differential diagnosis of thyrotoxicosis by doppler ultrasonography Murat Erdogan (Ankara, Turkey)

Olympic Hall II

12:30 -12:45 Lunch Break

(Olympic Hall II)

Poster discussion 1 Thyroid cell biology Chairperson: Pilar Santisteban (Madrid, Spain)

P001 NOVEL PEPTIDE ANALOG OF THYROID PEROXIDASE EPITOPE IN AUTOIMMUNE THYROID DISEASES

Shutova I.V., Gribovskaja O.V., Tsyganova O.V., Golubovich V.P. The Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus

P002 MODULATION OF IODIDE UPTAKE AND RETINOIC ACID RECEPTORS (RAR AND RXR) EXPRESSION BY THYROTROPIN AND RETINOIC ACID

Souza CL.E.¹, Coelho M.S.², Alves M.A.², Takyia M.Ch.², Nasciutti L.E.², **Carvalho P.D.**¹ ¹Instituto de Biofísica Carlos Chagas Filho, UFRJ, ²Departamento de Histologia e Embriologia, UFRJ

P003 IMPLICATION OF THE WNT PATHWAY IN THE DIFFERENTIATION AND TRANSFORMATION OF THE THYROID CELL

Sastre-Perona A., Moya C.M., Santisteban, P.

Fisiopatologia Endocrina y del Sistema Nervioso, CSIC-UAM, Instituto de Investigaciones Biomedicas, Madrid, Spain

P004 FOLLICULAR ORGANIZATION OF CULTURED THYROCYTES AFFECTS MARKER GENE EXPRESSION AND CALCIUM SIGNALLING DYNAMICS

Lorenz S.^{1, 2}, Ziesche S.¹, Leinung S.³, Aust G.³, Krohn K.^{1, 2}

¹University of Leipzig, Medical Faculty, 3rd Medical Dept., ²University of Leipzig, Medical Faculty, Interdisciplinary Center for Clinical Research, ³University of Leipzig, Medical Faculty, Clinic for Visceral, Thoracic, Vascular and Transplant Surgery

^{12:45-14:00} **Poster Discussion P001 to P058**



P005 COMPARISON OF EXPRESSED HUMAN AND MOUSE SODIUM IODIDE SYMPORTERS

Dayem M.¹, Basquin C.¹, Navarro V.¹, Carrier P.¹, Marsault R.¹, Huc S.², Darrouzet E.², Lindenthal S.¹, **Pourcher Th.**¹

¹TIRO, CEA DSV-iBEB-SBTN, CAL, University of Nice Sophia Antipolis, Nice, France, ²TIRO, CEA center of Valrho, DSV-iBEB-SBTN, Bagnols-sur-Ceze, France

P006 N6-ISOPENTENYLADENOSINE INDUCES APOPTOSIS IN THYROID CELL

Vitale M.¹, Di Matola T.², Laezza Ch.³, Moretti M.I.¹, Fenzi G.¹, Rossi G.², Bifulco M.⁴

¹Department of Endocrinologia e Oncologia Molecolare e Clinica, University of Naples Federico II, Naples, Italy, ²Department of Biologia e Patologia Cellulare e Molecolare, University of Naples Federico II, Naples, Italy, ³Institute of Endocrinologia e Oncologia, CNR, Naples, Italy, ⁴Department of Scienze Farmaceutiche, University of Salerno, Italy

P007 HIGH PREVALENCE OF TSHR/Gs-MUTATION-NEGATIVE CLONAL TOXIC THYROID NODULES IN A TURKISH COHORT

Krohn K.^{1, 2}, **Sancak S.**³, Jaeschke H.¹, Sen Leyla S.⁴, Güllüoglu M. B.⁴, Tanay Eren F.⁵, Sever Z.⁵, Akalin N. S.³, Paschke R.¹, Eszlinger M.¹

¹III Medical Department, University of Leipzig, Leipzig, Germany, ²IZKF Leipzig, University of Leipzig, Leipzig, Germany, ³Section of Endocrinology and Metabolism of Marmara University Medical School, Istanbul, Turkey, ⁴General Surgery Department of Marmara Medical School, Istanbul, Turkey, ⁵Department of Pathology of Marmara Medical School, Istanbul, Turkey

P008 PATHOGENIC CONSTITUTIVE ACTIVATION OF THE THYROTROPIN RECEPTOR CAUSED BY A NEWLY IDENTIFIED SINGLE SUBSTITUTION IN TRANSMEMBRANE HELIX 6

Kleinau G.¹, Winkler F.^{1,2}, Krause G.¹, Grüters A.², Biebermann H.² ¹Leibniz-Institut für Molekular Pharmakologie, Berlin, Germany, ²Institute for Experimental Pediatric Endocrinology, Charité Universitätsmedizin, Berlin, Germany

P009 FATE MAPPING REVEAL THAT MIDLINE THYROID PROGENITORS ARISE FROM SONIC HEDGEHOG (SHH) NEGATIVE FOREGUT ENDODERM BUT SHH POSITIVE CELLS ENTER THE THYROID VIA THE PHARYNGEAL POUCHES

<u>Nilsson M.</u>, Westerlund J., Fagman H.

Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, Göteborg University, Göteborg, Sweden

P010 EXPRESSION AND SUBCELLULAR LOCALIZATION OF JAB1 AND P27

Lee S., Ahn J., Chung Y.J.

Internal medicine, Chung-Ang University Hospital, Seoul, Korea

Poster Discussion 2

Thyroid Cancer 1

Chairperson: Jan Smit (Leiden, The Netherlands)

P011 VANDETANIB (100 MG) IN METASTATIC HEREDITARY MEDULLARY THYROID CANCER: A PHASE II OPEN-LABEL STUDY

Robinson B.¹, Paz-Ares L.², Krebs A.³, **Vasselli J.³**. Haddad R.⁴ ¹Kolling Institute of Medical Research, University of Sydney, Australia, ²Doce de Octubre University Hospital, Madrid, Spain, ³AstraZeneca, Wilmington, DE, USA, ⁴Dana-Farber Cancer Institute, Boston, MA, USA

P012 ROLE OF BASAL AND PENTAGASTRIN STIMULATED CALCITONIN IN TAKING THE DECISION TO PERFORM THYROIDECTOMY IN GENE CARRIERS OF RET MUTATIONS.

Romei C., Botici V., Cosci B., Renzini G., Molinaro E. , Agate L., Pinchera A., Elisei R. Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

202



P013 ANTI-TUMOR EFFECTS OF THE TYROSINE KINASE INHIBITORS SUNITINIB (SU11248) AND VANDETANIB (ZD6474) IN HUMAN THYROID CARCINOMA CELL LINES

Charalambous E.^{1, 2}, Kotoula V.¹, Hayden P.², McMillin W.D.², Negri J.², Mitsiades S.C.², <u>Mitsiades N.^{2, 3}</u> ¹Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ²Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA., ³Memorial Sloan Kettering Cancer Center, New York, USA

P014 PNEUMOTHORAX DUE TO MASSIVE TUMOR LYSIS IN A PATIENT WITH SORAFENIB THERAPY FOR METASTASIZED DIFFERENTIATED THYROID CARCINOMA

Hoftijzer H.¹, Heemstra K.¹, Blaauwwiekel E.², Corssmit E.¹, Romijn J.¹, Smit J.¹ ¹Department of Endocrinology and metabolism, Leiden University medical Center, Leiden, The Netherlands, ²Department of Internal Medicine, Nij Smellinghe Hospital, Drachten, The Netherlands

P015 HSP90 INHIBITION AS A NOVEL THERAPEUTIC APPROACH FOR THE TREATMENT OF AGGRESSIVE THYROID CARCINOMAS

McMillin W. D.¹, Kotoula V.², Negri J.¹, Hayden P.¹, Koletsa T.², Mitsiades S.C.¹, <u>Mitsiades N.^{1,3}</u> ¹Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA, ² Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, ³Memorial Sloan Kettering Cancer Center, New York, NY

P016 THE EFFECT OF PROLONGED ROSIGLITAZONE THERAPY IN PATIENTS WITH METASTATIC RADIOIODINE-NEGATIVE DIFFERENTIATED THYROID CARCINOMA

Kühne-Eversmann L.¹, Weiss M.², Pfluger T.², **Gaertner R.¹** ¹Department of Endocrinology, Medizinische Klinik Innenstadt, University of Munich, ²Department of Nuclear Medicine, Innenstadt, University of Munich

P017 PAPILLARY THYROID CANCERS <=2 CM: OUTCOME PREDICTORS AND IMPACT OF SURGICAL AND RADIOMETABOLIC TREATMENTS

Perrino M.¹, Vannucchi G.¹, Colombo C.¹, Vicentini L.², Chiti A.³, Beck Peccoz P.¹, Fugazzola L.¹ ¹Department of Medical Sciences, Endocrine Unit Unviversity of Milan, IRCCS Fondazione Policlinico, Milan, Italy, ²Endocrine Surgery Unit, IRCCS Fondazione Policlinico, Milan, Italy³, Nuclear Medicine Unit, IRCCS Istituto Clinico Humanitas, Milan, Italy

P018 PRIMARY TUMOUR DIAMETER AS A RISK FACTOR FOR METASTASES IN DIFFERENTIATED THYROID CARCINOMA

Luster M., Verburg F., Mäder U., Reiners Ch. University Clinic Würzburg, Würzburg, Germany

P019 BRAF EXPRESSION MAY HELP DEFINE PAPILLARY THYROID CANCER PROGNOSIS

Araujo P.PC¹, Tincani A.J.², Guilhen T.A.C.¹, Morari C.E.¹ Ward S.L.¹

¹Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School - FCM, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ²Head and Neck Division, Department of Surgery, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil

P020 CORRELATION BETWEEN BRAFV600E MUTATION AND CLINICAL AND PATHOLOGICAL FEATURES OF PAPILLARY THYROID CARCINOMAS IN THE CZECH REPUBLIC

<u>Sykorova V.</u>1, Dvorakova S.¹, Vaclavikova E.¹, Ryska A.², Kodetova D.³, Astl J.⁴, Duskova J.⁵, Smutny S.⁶, Vlcek P.⁷, Bendlova B.¹

¹Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic, ²Department of Pathology, Faculty of Medicine and University Hospital, Charles University, Hradec Kralove, Czech Republic, ³Institute of Pathology and Molecular Medicine, 2nd Medical Faculty, Charles University, Prague, Czech Republic, ⁴Department of ENT and Head and Neck Surgery, 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁵Institute of Pathology, 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁶Department of Surgery, 2nd Medical Faculty, Charles University, Prague, Czech Republic, Nuclear Medicine and Endocrinology, 2nd Medical Faculty, Charles University, Prague, Czech Republic

Poster Discussion 3

Graves Opthalmopathy and Graves disease

Chairperson: Luca Chiovato (Pisa, Italy)

P021 OVEREXPRESSION OF SFRP2, ABCG1 AND CPXM1 IN BOTH GRAVES OPHTHALMOPATHY AND ARM LYMPHEDEMA

<u>Vondrichova T.</u>^{1, 4}, Parikh H.⁴, Brorsson H.², Martensson T.², Asman P.³, Groop L.^{1, 4}, Hallengren B.^{1, 4}, Lantz M.^{1, 4}

¹Department of Endocrinology, Malmö University Hospital, Malmö, Sweden, ²Department of Plastic Surgery, Malmö University Hospital, Malmö, Sweden, ³Department of Ophthalmology, Malmö University Hospital, Malmö, Sweden, ⁴Lund University, Department of Clinical Sciences Malmö, Diabetes and Endocrinology, Malmö, Sweden

P022 OPHTHALMOPATHY EXACERBATION/OCCURRENCE DURING RADIOIODINE THERAPY OF GRAVES DISEASE - THE PROSPECTIVE STUDY

Król A.¹, **Krawczyk A.**¹, Nowak M.³, Zarudzki L.², Jurecka-Lubieniecka B.¹, Hasse-Lazar K.¹, Paliczka-Cieślik E.¹, Krajewska J.¹, Michalik B.¹, Jarząb B.¹

¹Department of Nuclear Medicine and Endocrine Oncology, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, ²Department of Radiodiagnostics, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, ³Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Poland

- P023 EFFECTS OF RADIOIODINE THERAPY ON THE REACTIVATION OF THYROID-ASSOCIATED ORBITOPATHY: ROLE OF PREVENTIVE TREATMENT WITH STEROIDS <u>Covelli D.</u>¹, Campi I.¹, Vannucchi G.¹, Dazzi D.¹, Currò N.², Simonetta S.², Beck-Peccoz P.¹, Salvi M.¹ ¹Endocrine Unit, Department of Medical Sciences, Fondazione Ospedale Policlinico IRCCS, University of Milan, ²Ophthalmology, Fondazione Ospedale Policlinico IRCCS, University of Milan
- P024 RESPONSE TO GLUCOCORTICOID THERAPY IN PATIENTS WITH GRAVES' OPHTHALMOPATHY <u>Beleslin B.</u>, Zarkovic M., Ciric J., Stojkovic M., Savic S., Trbojevic B. Institute of endocrinology, Belgrade, Serbia
- P025 RETROBULBAR IRRADIATION FOR GRAVES OPHTHALMOPATHY: A RETROSPECTIVE STUDY, EVALUATING THE EFFICACY OF DOSES BETWEEN 12-20GY

Johnson K. TM¹, Loesch C.², Esser J.¹, Mann K.³, Eckstein A.¹

¹Department of Ophthalmology University of Essen, Germany, ²Institute for Medical Informatics, Biometry and Epidemiology University of Essen, Germany, ³Department of Medicine, Division of Endocrinology University of Essen, Germany

P026 TSHR AUTOANTIBODIES IN THYROIDECTOMISED PATIENTS WITH GRAVES' DISEASE AND ASSOCIATED OPHTALMOPATHY DECREASE AFTER RETROBULBAR RADIATION THERAPY

Loos U.¹, Büsselmann I.², Schmitt Th.², Franz C.²

 1 University Ulm and KreLo GmbH Medical Diagnostics, Ulm, Germany, 2 KreLo GmbH Medical Diagnostics, Ulm, Germany

P027 THE CONSEQUENCES OF EXPERIENCED BODILY CHANGE ON INTERPERSONAL BEHAVIOUR IN PATIENTS WITH THYROID ASSOCIATED OPHTHALMOPATHY Jensen A. L.¹, Harder I.²

¹Department of Medical Endocrinology, Aarhus Hospital, Aarhus University Hospital, Denmark, ²Institute of Public Health, Department of Nursing Science, Faculty of Health Sciences, University of Aarhus, Denmark

P028 QUALITY OF LIFE IN THYROID PATIENTS: A NEW THYROID-SPECIFIC QUESTIONNAIRE DETECTED CLINICALLY MEANINGFUL DIFFERENCES BETWEEN PATIENTS WITH DISSIMILAR BENIGN THYROID DIAGNOSES

<u>Watt T.</u>¹, Rasmussen A.K.¹, Hegedüs L.², Bonnema, S.J.², Groenvold M.³, Bjorner J.B.⁴, Feldt-Rasmussen U.¹ ¹Dpt. of Endocrinology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Dpt.



of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark, ³Health Service Research, University of Copenhagen, Copenhagen, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark

P029 UNUSUAL PRESENTATION OF EUTHYROID GRAVES OPHTHALMOPATHY IN PREGNANCY

Germain S.², **Dagdelen S.**¹, Saha S.², Nelson-Piercy C.², Stanford M.², Gilbert J.¹, Carrol P.² ¹Endocrinology and Diabetes, King's College Hospital, London, UK, ²Gynecology and Obstetrics, Guys and St Thomas, NHS Trust, London, UK

P030 LONG-TERM CONTINUOUS ANTITHYROID TREATMENT OF HYPERTHYROIDISM

Azizi F., Ataie L., Mehrabi Y.

Research Institute for Endocrine Sciences, Endocrine Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, I.R. Iran

P031 PRECOCIOUS HYPOTHYROIDISM MECHANISMS AFTER RADIOIODINE TREATMENT IN GRAVES DISEASE

Proust-Lemoine E.¹, D' Herbomez M.², Marchandise X.², Wémeau J. L.¹ ¹Clinique Endocrinologique Marc Linquette, Lille Hospital, ²Service de Médecine Nucléaire, Hôpital Roger Salengro, Lille

P032 FULMINANT HEPATITIS DURING TREATMENT WITH PROPYLTHIOURACIL IN GRAVES' DISEASE: CASE REPORT

Alves A.C.¹, **Pavin E.J.**¹, Amorim E.G.¹, Tambascia M.A.¹, Silva B.P.¹, Ferrari M. T.M.¹, Pallone A.T.L.¹, Escanhoela C.H.², Zantut-Wittmann D.E.¹

¹Endocrinology Division, Department of Internal Medicine, School of Medical Sciences, State University of Campinas, ²Department of Anatomical Pathology, School of Medical Sciences, State University of Campinas, Sao Paolo, Brasil

Poster Discussion 4

Goitre 1 & iodine deficiency

Chairperson: Zvonko Kusic (Zagreb, Kroatia)

P033 EPIDEMIOLOGY OF IODINE DEFICIENCY AND THYROID FUNCTION DURING THE FIRST TRIMESTER OF NORMAL PREGNANCY IN NICE (FRANCE)

Brucker-Davis F.¹, Hieronimus S.¹, Ferrari P.², Zabeo L.¹, Berthier F.³, Baez E.¹, Brun V.², Bongain A.¹, Fenichel P.¹

¹Pole de Gynecologie-Obstetrique-Reproduction-Endocrinologie, CHU Nice, Nice France, ²Departement d'Hormonologie, CHU Nice, Nice France, ³Departement de Statistiques Biomedicales, CHU Nice, Nice France

P034 IODINE NUTRITION SURVEY AFTER UNIVERSAL SALT IODIZATION (USI) IMPLEMENTATION; THE CONSEQUENCE OF LOW UIC ON THYROID FUNCTION IN PREGNANT WOMEN (PW) AND NEONATE (OC) AT BIRTH

Simescu M.¹, Podia-Igna C.², Sava M.³, Colda I.⁴, Hazi G.⁵, Varciu M.⁶, Pelinescu O.⁷, Coamesu U.⁸, Totoianu D.¹⁰, Nitescu M.⁹

¹Thyroid Department, Institute of Endocrinology C.I. Parhon, Bucharest, Romania, ²Clinic of Endocrinology, Clinical Emergency Hospital Sibiu, Romania, ³Laboratory Department, Institute of Endocrinology C.I. Parhon, Bucharest, Romania, ⁴Public Epidemiology, County Hospital Bistrita, Romania, ⁵Laboratory Department, Clinic of Endocrinology Cluj-Napoca, Romania, ⁶Endocrinology Department, University of Medicine and Farmacy Brasov, Romania, ⁷Obstetric-Gynecology Department, University of Medicine and Farmacy Bucharest, Romania, ⁸Endocrinology Department, County Hospital Ramnicu Valcea, Romania, ⁹AST, Bucharest, Romania, ¹⁰UMF, Sibiu, Romania



P035 THE GOITER PREVALENCE AMONG SCHOOL AGE CHILDREN IN ANKARA BEFORE AND AFTER THE MANDATORY IODINATION OF THE TABLE SALTS (1997-2008)

Demir Ö.¹, Erdogan M.F.¹, Emral R.¹, Yılmaz A.E.², Kamel N.¹, Erdogan G.³

¹Ankara University, Faculty of Medicine, Endocrinology and Metabolic Diseases Department, ²Ankara Oncology Hospital, ³Ufuk University, Faculty of Medicine, Endocrinology and Metabolic Diseases Department

P036 URINARY IODINE CONCENTRATION, THYROID VOLUME AND FUNCTION TESTS IN IODINE-REPLETE PREGNANT WOMEN

Azizi F., Eini E., Delshad H., Hedayati M.

Institute for Endocrine Sciences, Shaheed Beheshti University of Medical Sciences, Tehran, I.R. Iran

P037 A CROSS SECTIONAL NATIONAL STUDY OF URINARY IODINE CONCENTRATION IN SCHOOL AGED CHILDREN

Nyström E.B., Eggertsen G., Filipsson R., Gramatkovski H., Hansson E., Hulthen M., Milakovic L., Mille Andersson M.

¹Department of Endocrinology, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Department of Oncology, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Department of Primary Health Care, Mölnlycke Primary Health Care and Research Centre, Mölnlycke, Sweden, ⁴Department of Endocrinology, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Gothenburg, Gothenburg, Sweden, ⁵Department of Clinical Nutrition, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁶Department of Radiation Physics, University of Gothenburg, Gothenburg, Sweden, ⁷Department of Clinical Nutrition, Sahlgrenska Academy at University, Sweden, ⁸Department of Primary Health Care, Mölnlycke Primary Health Care and Research Centre, Mölnlycke, Sweden, ⁸Department of Primary Health Care, Nölnlycke Primary Health Care and Research Centre, Mölnlycke, Sweden, ⁹Laboratory for Human Nutrition, Institute of Food Science and Nutrition, Swiss Federal Institute of Technology Zürich, Zürich, Switzerland

P038 SMOKING AS A RISK FACTOR FOR THYROID VOLUME PROGRESSION AND INCIDENT GOITER IN A REGION WITH IMPROVED IODINE SUPPLY

Ittermann T.^{1, 4}, Schmidt O.C.¹, Kramer A.², Below H.², John U.³, Thamm M.⁶, Wallaschofski H.⁵, Völzke H.¹

¹Institute for Community Medicine; ²Institute of Hygiene and Environmental Medicine; ³Institute of Epidemiology and Social Medicine; ⁴Institute of Clinical Chemistry and Laboratory Medicine; ⁵Department of Gastroenterology, Endocrinology and Nutrition; University of Greifswald; ⁶ Robert-Koch-Institute, Berlin, Germany

P039 IODIDE AVAILABILITY DURING PREGNANCY: ROLE OF DIETARY HABITS AND GEOGRAPHICAL ORIGIN <u>Mian C.</u>¹, Vitaliano P.¹, Pozza D.¹, Pitton M.², Callegari G.³, Nacamulli D.¹, Busnardo B.¹, Mantero F.¹, Girelli M.E.¹

¹Department of Medical & Surgical Sciences; Endocrinology Unit University of Padua, Padua, Italy, ²Department of Pharmacology and Anaesthesiology University of Padua, ³Gynaecological Consulting-Rooms, Padua, Italy

P040 REFERENCE RANGES FOR THYROID-STIMULATING HORMONE AND PREVALENCE OF THYROID DISORDERS AT ADOLESCENTS IN MILD IODINE-DEFICIENCIES REGION

<u>Kiyayev A.</u>¹, Savelyev L.¹, Fadeev V.², Tsvirenko S.¹ ¹Regional Child Hospital, Ekaterinburg, Russia, ²Federal Endocrine Research Center, Moscow, Russia

P041 TSH AND THYROID HORMONE VALUES IN SCHOOLCHILDREN LIVING IN AN AREA WITH LONG-STANDING IODINE SUFFICIENCY: CORRELATION WITH GENDER, PUBERTY AND ADIPOSITY

Kaloumenou I.¹, Duntas L.², Mastorakos G.², Alevizaki M.², Mantzou E.², Mengreli Ch.³, Chiotis D.¹, Papassotiriou I.⁴, Chrousos G.P.¹, Dacou-Voutetakis C.¹

¹Endocrine Unit, First Department of Pediatrics, Athens University School of Medicine, ²Department of Endocrinology and Metabolism "Evgenidion" Hospital, Athens University School of Medicine, ³Institute of Child Health, "Agia Sofia" Childrens Hospital, ⁴Department of Clinical Biochemistry, "Agia Sofia" Childrens Hospital, Athens, Greece



P042 RELATIONSHIP BETWEEN IODINE STATUS, THYROID ABNORMALITIES AND GASTRIC CANCER

Haghpanah V.¹, Roushandel G. R.², Tabeizadeh M.¹, Adabi K.², Keshtkar A.A.², Heshmat R.¹, Semnani S.², Larijani B.¹

¹Endocrinology and Metabolism Research Centre, University of Tehran/Medical Sciences, Tehran, Iran, ²Gastroenterology and Hepatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran

P043 DOES RESPONSE BIAS INFLUENCE POPULATION STUDIES OF THYROID DISORDERS?

<u>Völzke H.</u>, Haring R., Schmidt C., Alte D., Kramer A., Hoffmann W., John U., Wallaschofski H. University of Greifswald, Greifswald, Germany

Poster Discussion 5 Clinical thyroidology 1- Cardiovascular Chairperson: Apostolos Vagenakis (Patra, Greece)

P044 THE BENEFICIAL EFFECT OF L-THYROXINE ON CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM CAUSED BY AUTOIMMUNE THYROIDITIS

Neves C.¹, Alves M.¹, Pereira M.¹, Ramalho R.², Ramos J.P.², Guimaraes C.², Carvalho E.¹, Carvalho D.¹, Delgado J. L.², Medina J.L.¹

¹Endocrinology Service, S. Joao Hospital, Faculty of Medicine, University of Porto, Portugal, ²Immunology Service, S. Joao Hospital, Faculty of Medicine, University of Porto, Portugal

P045 REMODELING THE LEFT VENTRICLE IN PATIENTS WITH THYROTOXICOSIS

Sviridenko N.Y.¹, Buziashvili Y.I.², Tugeeva E.F.², Aripov M.A.², Sementsova E.M.¹ ¹Therapy department, Endocrinological Research Centre, Federal Agency of High-Tech Medicine, Moscow, Russia, ²Institution of cardiac surgery Bakoulev scientific center of cardiovascular surgery

P046 MYOCARDIAL REGIONAL LEFT VENTRICULAR DIASTOLIC FUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH AUTOIMMUNE THYROIDITIS AND SUBCLINICAL HYPOTHYROIDISM

Strongin L.G.¹, Nekrasova T.A.¹, Ledentsova O.V.², Kasakova L.V.¹, Lukushkina A.Y.¹ ¹Endocrinology department, Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia, ²Nizhny Novgorod clinical diagnostic center

P047 ASSOCIATION OF THYROID FUNCTION WITH ARTERIAL PRESSURE IN EUTHYROID INDIVIDUALS

Alevizaki M.¹, Saltiki K.², Voidonikola P.³, Anastasiou E.², Stamatelopulos K.³, Papamichael Ch.³ ¹Endocrine Unit, Evgenidion Hospital, Athens University School of Medicine, Greece, ²Dept Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Greece., ³Vascular Laboratory, Dept of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine

P048 THYROID FUNCTION AND LIPOPROTEIN PROFILE: A CROSS-SECTIONAL STUDY IN THYROID DISEASE PATIENTS

Tognini S.¹, Dardano A.¹, Polini A.¹, Colato C.², Ferdeghini M.², Monzani F.¹ ¹Department of Internal Medicine, University of Pisa, Italy, ²Department of Pathology, University of Verona, Italy, ³Department of Morphological and Biomedical Sciences, University of Verona, Italy

P049 HYPOTHYROIDISM AND VASCULAR REACTIVITY: A NEW PERSPECTIVE

Lupoli G.A.¹, Panico A.¹, Fonderico F.¹, Assante R.¹, Martinelli A.¹, Granieri L.¹, Marano A.², Napoli R.², Sacca L.², Lupoli G.¹

¹Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica - Universita degli Studi "Federico II" - Napoli, Italy, ²Dipartimento di Medicina Interna e Malattie Cardiovascolari - Universita degli Studi "Federico II" - Napoli, Italy



P050 THYROID HORMONE THERAPY IN HYPOTHYROID PATIENTS UNDERGOING CORONARY ANGIOGRAPHY AND CORONARY ARTERIAL BYPASS SURGERY Milicevic Z.

Institute of Nuclear Sciences Vinca, Lab. Mol. Biol. Endocrinol, Belgrade, Servia

P051 THYROID FUNCTION, SERUM LIPIDS AND INSULIN RESISTANCE IN PATIENTS WITH AUTOIMMUNE THYROIDITIS

<u>Medina J.L.</u>¹, Neves C.¹, Alves M.¹, Pereira M.¹, Ramalho R.², Ramos J.P.², Guimaraes C.², Pimentel I.¹, Carvalho D.¹, Delgado J.L.²

¹Endocrinology Service, S. Joao Hospital, Faculty of Medicine, University of Porto, Portugal, ²Immunology Service, S. Joao Hospital, Faculty of Medicine, University of Porto, Portugal

P052 THYROID HORMONES LEVELS AND THEIR RELATION WITH METABOLIC PARAMETERS IN A GROUP OF OBESE EUTHYROID PATIENTS

Sirbu A.^{1, 2}, Barbu C.^{1, 2}, Florea S.², Trifanescu R.^{1, 3}, Fica S.^{1, 2} ¹Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²Elias University Hospital, Bucharest, Romania, ³C. I.Parhon Institute of Endocrinology, Bucharest, Romania

P053 BODY WEIGHT AND COMPOSITION CHANGES AFTER SHORT-TERM MEDICAL TREATMENT OF THYROID DYSFUNCTION

Papadopoulou F., Pontikides N., Kaltsas Th., Tziomalos K., Karras S., Kaprara Ath., Stafilidou A., Krassas G. E.

Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece

P054 SERUM IL-6 AND CRP AS MARKERS OF THYROID DESTRUCTION IN PATIENTS WITH DIFFERENT TYPES OF DESTRUCTIVE THYROIDITIS

Platonova N., **Molashenko N.**, Kobelnitskaya L., Sviridenko N., Troshina E. National Research Center for Endocrinology, Moscow, Russia

P055 AMIODARONE & THYROID DYSFUNCTION IN A SCOTTISH DISTRICT GENERAL HOSPITAL <u>Ghosh S.</u>, Teoh W. L., Haxton Ch., Cottrell R., Elhadd T., Malik I., Collier A. Department of General Medicine, Ayr Hospital, Ayr Scotland, United Kingdom

P056 CORONAROGRAPHY RESULTS IN PATIENTS WITH MILD THYROID FAILURE <u>Grineva E.</u>¹, Volkova A.², Dora S.³ ¹Saint-Petersburg Medical University named acad. I.P. Pavlov, St Petersburg, Russia

P057 99MTC-SESTA-MIBI THYROID SCAN IN THE DIFFERENTIAL DIAGNOSIS OF AMIODARONE-INDUCED THYROTOXICOSIS

Mariotti S.¹, Cocco M. Ch.², Serra A.³, Boi F.⁴, Loy M.⁵, Piga M.⁶

¹Endocrinology, Department of Medical Sciences "M. Aresu" University of Cagliari, Monserrato (Cagliari), Italy, ²Endocrinology, Department of Medical Sciences "M. Aresu" University of Cagliari, Monserrato (Cagliari), Italy, ³Nuclear Medicine, Department of Medical Sciences "M. Aresu" University of Cagliari, Monserrato (Cagliari), Italy, ⁴Endocrinology, Department of Medical Sciences "M. Aresu" University of Cagliari, Monserrato (Cagliari), Italy, ⁵Ultrasound Unit University of Cagliari, Monserrato (Cagliari), Italy, ⁶Nuclear Medicine, Department of Medical Sciences "M. Aresu" University of Cagliari), Italy, ⁶Nuclear Medicine, Department of Medical Sciences "M. Aresu" University of Cagliari, Monserrato (Cagliari), Italy

P058 99MTC-SESTAMIBI THYROID IMAGING IN PATIENTS ON CHRONIC AMIODARONE TREATMENT: A COMPARISON WITH 99MTC-PERTECHNETATE IMAGING

Oki G.¹, **Zantut-Wittmann D.E.**², Santos/A. D'O.², Guariento M.H.³, Tambascia M.A.¹, Almeida E.A.³, Etchebehere E.CSC.¹, Camargo E.E.¹, Ramos C.D.¹

¹Nuclear Medicine Service, School of Medical Sciences, State University of Campinas, ²Endocrinology Division, School of Medical Sciences, State University of Campinas, ³Internal Medicine Division, School of Medical Sciences, State University of Campinas, Sao Paolo, Brasil



Olympic Hall I

14:00-14:50 Special Lecture

The Revolution in intercellular communication: Looking back and looking ahead Jesse Roth [New York, USA]

Meliton Hotel - Erato Hall

15:00-15:45 Meet the Experts 1 Stem cell debate-pro and con Jacques Dumont (Brussels, Belgium) Michael Derwahl (Berlin, Germany)

Meliton Hotel -Terpsichori Hall

15:00-15:45 Meet the Experts 2 Factors affecting L-thyrotoxine absorption Furio Pacini (Siena, Italy)

Olympic Hall I

15:00-15:45 Meet the Experts 3 Tumour burden and progression rate and RECIST Lars Bastholt (Odense, Denmark)

Olympic Hall III

15:00-15:45 Meet the Experts 4 Thyrostimulin – fact or fiction Mikael Lantz (Lund, Sweden)

Olympic Hall II

15:45-16:00 Coffee Break

Olympic Hall I

16:00-18:00 Symposium 3 (Translational) Thyroid hormone & metabolism Chairpersons: Graham Williams (London, UK) Fotini Papadopoulou (Thessaloniki, Greece)

> Hypothalamus, HPT axis and energy metabolism Csaba Fekete (Budapest, Hungary)

Metabolic consequences of a dominant-negative mutation in TRa1 Jens Mittag (Stockholm, Sweden)

Metabolic effects of selective thyroid hormone receptor modulators Frederic Flamant (Lyon, France)

Olympic Hall III)

16:00-18:00 Oral session 1

Thyroid cancer 1 Chairpersons: Massimo Santoro (Naples, Italy) Barbara Vlassopoulou (Athens, Greece)



007 TELOMERASE-DRIVEN EXPRESSION OF THE SODIUM IODIDE SYMPORTER (NIS) FOR IN VIVO RADIOIODIDE IMAGING AND TREATMENT OF CANCER: A NEW BROAD-SPECTRUM NIS-MEDIATED ANTITUMOUR APPROACH

Riesco-Eizaguirre G.¹, De La Vieja A.², Rodriguez-García I.², Martín-Duque P.³, Vassaux G.⁴, Santisteban P.² ¹Hospital Universitario La Paz, Madrid, Spain, ²Instituto de Investigaciones Biomedicas "Alberto Sols", CSIC-UAM, Madrid, Spain, ³Departamento de Biotecnologia, Universidad Francisco de Vitoria, Madrid, Spain, ⁴Centre for Molecular Oncology, Institute of Cancer, Queen Mary's School of Medicine and Dentistry, London, UK

008 CLINICAL UTILITY OF A SECOND RECOMBINANT HUMAN TSH STIMULATION IN DIFFERENTIATED THYROID CANCER PATIENTS

Torlontano M.¹, Crocetti U.¹, Durante C.⁴, Attard M.⁵, Maniglia A.⁵, Tumino S.⁶, Bruno R.⁷, Bonfitto N², Dicembrino F.³, Varraso A.³, Meringolo D.⁸, Filetti S.⁴, Trischitta V.^{1,4,9}

¹Units of Endocrinology, ²Thoracic Surgery, ³Nuclear Medicine, Scientific Institute Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy, ⁴Department of Clinical Sciences, Sapienza University, Rome, Italy, ⁵Unit of Endocrinology, Cervello Hospital, Palermo, Italy, ⁶Department of Biomedical Sciences, University of Catania, Catania, Italy, ⁷Unit of Endocrinology, Tinchi-Pisticci Hospital, Matera, Italy, ⁸Unit of Endocrinology, Bentivoglio Hospital, Bologna, Italy, ⁹Casa Sollievo della Sofferenza- Mendel Institute, Rome, Italy

009 RADIOIODINE IS AN EFFECTIVE AND SAFE ADJUVANT TREATMENT IN CHILDREN WITH DIFFERENTIATED THYROID CANCER (DTC)

Handkiewicz-Junak D., Kropinska A., Krajewska J., Roskosz J., Puch Z., Olczyk T., Jarzab B. Department of Nuclear Medicine and Endocrine Oncology, MSC Memorial Cancer and Institute of Oncology, Gliwice Branch, Gliwice, Poland

010 HIF-1A MODULATES PROLIFERATION AND DIFFERENTIATION IN THYROID CARCINOMAS VIA PI3K AND MAPK/ERK SIGNALLING

Williams K.¹, Cowen R.¹, von Wasielewski R.², Resch J.⁴, West C.³, **Brabant G.**⁴ ¹School of Pharmaccy, University of Manchester, UK, ²Dept. of Pathology, Medizinische Hochschule Hannover, Germany, ³Dept. Radiation Oncology, Manchester, UK, ⁴Dept. of Endocrinology, Christie Hospital, Manchester, UK

011 MCT8 EXPRESSION IN THYROID CARCINOMAS

Motamedi, M.¹, von Wasielewski R.¹, Friesema Ch. E.², Visser J. T.² **Brabant G.**³ ¹Institut für Pathologie, Medizinische Hochschule Hannover, Germany, ²Department of Internal Medicine, EMCR, Rotterdam, Netherlands, ³Dept. of Endocrinology, Christie Hospital, Manchester, UK

012 IMMUNOANALYSIS INDICATES THAT THE SODIUM IODIDE SYMPORTER IS NOT OVEREXPRESSED IN INTRACELLULAR COMPARTMENTS IN THYROID AND BREAST CANCERS

Peyrottes I.¹, Navarro V.², **Ondo-Mendez A.**⁴, Marcellin D.³, Bellanger L.³, Marsault R.², Lindenthal S.², Ettore F.¹, Spinel-Gomez C.⁵, Pourcher T.²

¹Department of Pathology, Center Antoine Lacassagne, Nice, France, ²TIRO, CEA DSV-iBEB-SBTN, CAL, University of Nice Sophia Antipolis, Nice, France, ³CEA center of Marcoule (D.M., L.B.),DSViBEB-SBTN, Bagnols-sur-Ceze, France, ⁴TIRO, CEA DSV-iBEB-SBTN, CAL, University of Nice Sophia Antipolis, Nice, France, Biophysics Laboratory, International Center of Physics, Bogota, Colombia/ Chemistry Department, National University of Colombia, Bogota, Colombia, ⁵Biophysics

Laboratory, International Center of Physics, Bogota, Colombia, Biology Department, National University of Colombia, Bogota, Colombia

013 INFLUENCES OF SHORT-TERM HYPOTHYROIDISM IN BODY WEIGHT, LIPID METABOLISM AND BLOOD PRESSURE IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

Kalarrytou M.¹, Mantzou E.¹, Boutsiadis A.¹, Loukari E.¹, Pitsouni E.², **Duntas L.**¹ ¹Endocrine Unit, Evgenidion Hospital, University of Athens, Greece, ²Biomedical Laboratory, Evgenidion Hospital, University of Athens, Greece 20



014 IN SITU DETECTION OF MICRORNAS 146B, 221 AND 222 IN FORMALIN-FIXED, PARAFFIN-EMBEDDED HUMAN CARCINOMA TISSUES REVEALS SPECIFIC EXPRESSION PATTERNS IN THYROID CARCINOMAS

Kotoula V.¹, Charalambous E.¹, Koletsa T.¹, Pliakos I.¹, Karayannopoulou G.¹,

Karkavelas G.¹, Mitsiades S. C.², Mitsiades N.^{2, 3}

¹Dept. of Pathology, School of Medicine, Aristotle University, Thessaloniki, Greece, ²Dept. of Medical Oncology, Dana Farber Cancer Institute, and Dept. of Medicine, Harvard Medical School, Boston MA, USA, ³Memorial Sloan Kettering Cancer Center, New York, USA



Monday, September 22nd, 2008

Olympic Hall I

06:45-07:15 Breakfast (at the Meliton and Sithonia Thalasso & Spa)

07:15-08:30 **Satellite Symposium (MERCK SERONO) Clinical highlights in thyroidology** Chairperson: **George J. Kahaly** (Mainz, Germany)

> T4 replacement in primary hypothyroidism: still suboptimal? Wilmar M. Wiersinga (Amsterdam, The Netherlands)

Changes in the autoimmunity of Graves' disease after various therapies What are the clinical consequences? Peter Laurberg (Aalborg, Denmark)

Subclinical hypothyroidism and atherosclerosis- where is the evidence? Leonidas Duntas (Athens, Greece)

08:30-10:30 Oral session 2

Graves orbitopathy and thyroid autoimmunity Chairpersons: Luigi Bartalena (Varese, Italy) Konstantinos Boboridis (Thessaloniki, Greece)

015 HUMAN HERPESVIRUS TYPE 6 (HHV6) AND 7 (HHV7) INFECTION MAY INCREASE THE SUSCEPTIBILITY TO GRAVES⁻ DISEASE IN INDIVIDUALS WITH INHERITED DIMINISHED TP53 APOPTOTIC FUNCTION Leite J.L.¹, Bufalo N.E.¹, Santos R.B.², Romaldini J.H.², Ward L.S.¹

¹Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School - FCM, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ²Endocrinology, Pontifica Universidade Catolica de Campinas, Sao Paulo, Brazil

016 CLINICAL EVALUATION OF THE FIRST AUTOMATED TSH RECEPTOR AUTOANTIBODY ASSAY: AN INTERNATIONAL MULTICENTER TRIAL

Schott M.¹, Broecker-Preuss M.², Casati M.³, van Helden J.⁵, Inomata K.⁶, Kratzsch J.⁷, Mann K.², Camara Mas J.⁴, Miyazaki N.⁸, Navarro Moreno M. A.⁴, Murakami T.⁶, Yoshimura Noh J.⁸, Roth H. J.⁹, Scherbaum A. W.¹, Hermsen D.¹⁰

¹Department of Endocrinology, Diabetes and Rheumatology, University Hospital Duesseldorf, ²Department of Endocrinology, University Hospital Essen, Essen, Germany, ³A.O. San Gerardo, Monza, Italy, ⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵MVZ für Labormedizin, Mönchengladbach, Germany, ⁶Noguchi Thyroid Clinic and Hospital Foundation, Ooita, Japan, ⁷Universitätsklinikum Leipzig, Germany, ⁸ITO Hospital, Tokyo, Japan, ⁹Labor Limbach, Heidelberg, Germany, ¹⁰Institute of Clinical Chemistry and Laboratory medicine, University Hospital Duesseldorf, Germany

017 INDENTIFICATION OF KEY RESIDUES ON THYROID PEROXIDASE CONTRIBUTING TO THE BINDING OF MOUSE MONOCLONAL ANTIBODIES SPECIFIC FOR IMMUNODOMINANT REGIONS

Godlewska M.¹, Gora M.^{1, 2}, Krasuska W.¹, Banga J.P.³, Gardas A.¹

¹Department of Biochemistry and Molecular Biology, Medical Centre of Postgraduate Education, Warsaw, Poland, ²Department of Genetics, Institute of Biochemistry and Biophysics PAS, Warsaw, Poland, ³Division of Gene and Cell Based Therapy, King's College London School of Medicine, London, UK



018 EXPRESSION OF TH1 (CXCL9, CXCL11) AND TH2 (CCL2) CHEMOKINES IN THYROCYTES, FIBROBLASTS AND PREADIPOCYTES FROM PATIENTS WITH GRAVES OPHTHALMOPATHY; MODULATION BY PPARGAMMA AGONISTS

Antonelli A.¹, Fallahi P.¹, Ferrari S. M.¹, Romagnani P.², Franceschini, S.S.³, Serio M.², Ferrannini E.¹ ¹Department of Internal Medicine, University of Pisa; Pisa; Italy,²Department of Clinical Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy, ³Otorhinolaryngology Unit, University of Pisa-School of Medicine, Pisa, Italy

019 INDUCTION OF HYALURONAN PRODUCTION IN DIFFERENTIATED HUMAN ORBITAL FIBROBLASTS BY FORSKOLIN, BUT NOT BY TSH OR GRAVES IGG

Van Zeijl C. J.J.¹, Surovtseva O.V.¹, Mourits M.P.², Fliers E.¹, Wiersinga W.M.¹, Boelen A.¹

¹Department of Endocrinology & Metabolism, Academical Medical Center, University of Amsterdam, The Netherlands,20rbita Center, Department of Ophthalmology, Academical Medical Center, University of Amsterdam, The Netherlands

020 THE EFFECT OF RITUXIMAB ON IL-6/SIL-6R AND CXCL10 SECRETION AND TSH-RECEPTOR STIMULATING ANTIBODIES IN PATIENTS WITH ACTIVE THYROID-ASSOCIATED ORBITOPATHY Vannucchi G.¹, Campi I.¹, Bonomi M.¹, Covelli D., Dazzi D., Currò N., Bonara P., Persani L.¹, Beck-Peccoz

P.¹, Salvi M.¹

¹Dept. of Medical Sciences, University of Milan, Ist. Auxologico Italiano IRCCS and Fondazione Ospedale Policlinico IRCCS, Milano, ²Ophthalmology, Internal Medicine, University of Milan

021 GENETIC AND NON GENETIC RISK FACTORS FOR THE OCCURRENCE OF OPHTALMOPATHY IN THE COURSE OF GRAVES DISEASE

Jurecka-Lubieniecka B.¹, Polanska J.², <u>Kula D.</u>¹, Krawczyk A.¹, Zebracka - Gala J.¹, Gubala E.¹, Stechly T.¹, Tyszkiewicz T.¹, Jarzab B.¹

¹MSC Memorial Cancer Center and Institute of Oncology, Gliwice, Poland, ²Institute of Automatic Control, Silesian University of Technology, Gliwice, Poland

022 PSYCHOSOCIAL ASSESSMENT IN 250 CONSECUTIVE PATIENTS WITH GRAVES⁻ ORBITOPATHY Ponto K.A., Pitz S., Hommel G., <u>Kahaly G.J.</u> Gutenberg University, Mainz, Germany

(Olympic Hall III)

08:30-10:30 Oral session 3 Thyroid development and functions Chairpersons: Mariastella Zannini (Naples, Italy) Sofia Tseleni-Balafouta (Athens, Greece)

023 THE ROLE OF SONIC HEDGEHOG PATHWAY IN THYROID ORGANOGENESIS <u>Recacha P.</u>, Santisteban P. Endocrine and Nervous System physiopathology, Instituto de Investigaciones Biomédicas, CSIC-UAM, Madrid, Spain

024 NOVEL INSIGHTS INTO THYROID GENE EXPRESSION IN NON-MAMMALIAN VERTEBRATES -COMPARATIVE STUDIES USING XENOPUS LAEVIS AS A MODEL ORGANISM

<u>Opitz R.</u>, Lorenz C., Trubiroha A., Kloas W. Department of Inland Fisheries, Leibniz-Institute of Freshwater Ecology and Inland Fisheries, Berlin, Germany

025 CONSTITUTIVELY ACTIVE TSHR MUTANTS DISPLAY PROFOUND ALTERATION OF THEIR ALLOSTERIC BEHAVIOR FOR TSH BINDING

Zoenen M.¹, Urizar E.², Vassart G.³, **Costagliola S.**¹

¹IRIBHM, Universite Libre de Bruxelles, Campus Erasme, B-1070 Brussels, Belgium, ²Center for Molecular Recognition, Columbia University, New York, USA, ³Service de Genetique Medicale, Hopital Erasme, Brussels, Belgium

24



026 THE SUPERAGONISTIC ACTIVITY OF BOVINE TSH AND THE HUMAN TSH ANALOG TR1401 ARE MEDIATED BY THE HUMAN TSH RECEPTOR HINGE REGION

Mueller S.¹, Szkudlinski W. M.² Jaeschke H.¹ Kleinau G.³ Krause G.³ Paschke R.¹ ¹III Medical Department, University of Leipzig, Leipzig, Germany, ²Trophogen, Inc., Rockville, MD, USA, ³Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany

027 DNA-PK INHIBITION AGGRAVATES DOWN-REGULATION OF NIS- MEDIATED IODIDE-TRANSPORT IN NORMAL CULTURED THYROCYTES SUBJECTED TO GENOTOXIC STRESS Nordén M. M., Carlsson T., Nilsson M.

¹Biomedicine, Sahlgrenska Academy Gothenburg University, Gothenburg, Sweden

028 LARGE-SCALE MOLECULAR SCREEN OF DUOX2 IN THYROID DYSHORMONOGENESIS

Ventura P.S.¹, Cavarzere P.², Albisu M.³, Audi L.³, Drop S. L. S.⁴, Carrascosa A.³, Leger J.⁵, Polak M.², Visser T. J.¹, **Moreno J. C.¹**

¹Dept.InternalMedicine, ErasmusMedicalCenter, Rotterdam, The Netherlands, ²PediatricEndocrinology Necker-Enfants Malades Hospital, Paris, France, ³PediatricEndocrinology, Vall dHebron Hospital, Barcelona, Spain, ⁴PediatricEndocrinology, Sophia Children Hospital, Rotterdam, The Netherlands, ⁵PediatricEndocrinology, Robert Debre Hospital, Paris, France

029 MONOALLELIC MUTATIONS IN DUOXA2AREASSOCIATED WITH MILD PERMANENT HYPOTHYROIDISM AND GOITER

Ventura P.S.¹, Azcona C.², Clemente M.³, Albisu M.³, Audi L.³, Carrascosa A.³ Visser T.J.¹, <u>Moreno J. C.</u>¹ ¹Dept. Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, ²Pediatrics, University Clinic of Navarra, Pamplona, Spain, ³Pediatric Endocrinology, Vall d Hebron Hospital, Barcelona, Spain

030 GENETIC CHARACTERIZATION OF IODIDE ORGANIFICATION DEFECTS

Fugazzola L.¹, Cortinovis F.², Zamproni I.², Vigone M. C.², Muzza M.¹, Cordella D.³, Beck-Peccoz P.¹, Refetoff S.⁴, Weber G.², Persani L.³

¹Dept. of Medical Sciences, Endocrine Unit University of Milan, IRCCS Fondazione Policlinico, Milan, Italy, ²Department of Pediatrics, Lab of Pediatric Endocrinology University Vita-Salute S. Raffaele, Milan, Italy, ³Dept. of Medical Sciences University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Depts of Medicine and Pediatrics, University of Chicago, Illinois, USA

Olympic Hall II

10:30-11:00 Coffee Break

Olympic Hall I

11:00-12:30 Symposium 4 (Educational) Thyroid cancer classification & diagnosis: The future Chairpersons: Martin Schlumberger (Paris, France) Iraklis Vainas (Thessaloniki, Greece)

> Discussant 1 Manuel Sobrinho Simoes (Porto, Portugal)

Discussant 2 Dillwyn Williams (Cambridge, UK)



Olympic Hall III

11:00-12:30 Symposium 5 (Translational) Congenital dyshormogenesis, goiter and the thyroxisome Chairpersons: Annette Grueters-Kieslich (Berlin, Germany) John Giovos (Thessaloniki, Greece)

> **Dual oxidase maturation factor and congenital hypothyroidism Luca Persani** (Milan, Italy)

Dehalogenase Jose Moreno (Rotterdam, The Netherlands)

Thyrocyte-specific Gq/G11 deficiency impairs thyroid function Jukka Kero (Turku, Finland)

Olympic Hall II

- 12:30-12:45 Lunch Break
- 12:45-14:00 Poster Discussion P059 to P119

Poster Discussion 6 Thyroid hormone metabolism and action Chairperson: Theo Visser (Rotterdam, The Netherlands)

P059 CHANGES IN RAT FATTY LIVER PROTEOME FOLLOWING 3,5-DIIODOTHYRONINE TREATMENT: A COMBINED BLUE NATIVE- AND 2D-ELECTROPHORESYS APPROACH

<u>Silvestri E.</u>¹, Burrone L.¹, Lombardi A.², De Lange P.³, Mainieri D.¹, Mollica M.², Lanni A.³, Goglia F.¹, Maria M.¹

¹Dip Scienze Biologiche ed Ambientali, Universita del Sannio, Benevento, Italy, ²Dip Scienze Biologiche, Universita Federico II, Napoli, Italy, ³Dip Scienze della Vita, SUN, Caserta, Italy

P060 EFFECTS OF T3 AND GC1 ON UCP1 AND D2 DEIODINASE IN BROWN ADIPOCYTES

Martinez-de-Mena R.¹, Scanlan T.S.², **Obregon M.J.**¹ ¹Fisiopatologia Endocrina y del sistema Nervioso, Inst. Investigaciones Biomedicas, CSIC, Madrid, Spain, ²Dpt.Pharm Chem& Cell Mol Pharmacol, Univ California, San Francisco, California, USA

P061 SHORT TERM EFFECTS OF 3,5-DIIODO-L-THYRONINE IN INDUCING FATTY ACID OXIDATION RATE AND THERMOGENESIS IN RAT SKELETAL MUSCLE MITOCHONDRIA

Lombardi A.¹, Busiello R.A.¹, De Lange P.², Silvestri E.³, Lionetti L.¹, Lanni A.², Moreno M.³, Goglia F.³ ¹Dip Scienze Biologiche, Università Federico II, Napoli, Italy, ²Dip Scienze della Vita, SUN, Napoli, Italy, ³Dip Scienze Biologiche ed Ambientali, Università del Sannio, Benevento, Italy

P062 NON GENOMIC EFFECTS OF 3,5,3-L-TRIIODOTHYRONINE THROUGH AMPK/ACC AND AKT/PKB SIGNALING: RELATION TO CHANGES IN FUEL METABOLISM AND MYOSIN HEAVY CHAIN PROTEIN CONTENT IN RAT GASTROCNEMIUS MUSCLE IN VIVO

De Lange P.¹, Senese R.¹, Cioffi F.¹, Moreno M.², Lombardi A.³, Silvestri E.², Valli V.¹, Goglia F.², Lanni A.¹ ¹Dip Scienze della Vita, SUN, Caserta, Italy, ²Dip Scienze Biologiche ed Ambientali, Universita del Sannio, Benevento, Italy, ³Dip Scienze Biologiche, Universita Federico II, Napoli, Italy

P063 NUCLEAR THYROID HORMONE RECEPTORS: EFFECTS OF VINCLOZOLIN, BISPHENOL-A, AND GENISTEIN IN HUMAN MCF-7 CELLS AND RAT LIVER

Brtko J.¹, Macejova D.¹, Ondkova S.¹, Fickova M.¹, Laudet V.²

23

24



¹Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic, ²Ecole Normale Superieure de Lyon, UMR 5161 du CNRS, Lyon, France

P064 ABERRANT EXPRESSION OF HUMAN THYROID HORMONE RECEPTOR BETA 1 PROTEIN MAY BE REGULATED BY ALTERNATIVE UNTRANSLATED REGIONS OF THRB1 MRNA IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC)

Master A.¹, Piekielko-Witkowska A.¹, Poplawski P.¹, Lampkowska J.¹, Wojcicka A.¹, Brozda I.¹, Tanski Z.²,. Williams G. R³, Nauman A.¹

¹Medical Center of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, ²Province Hospital, Department of Urology, Ostroleka, Poland, ³Molecular Endocrinology Group, Imperial College London, MRC Clinical Sciences Centre, Hammersmith Hospital, London, UK

P065 OXIDATIVE STRESS AND UV RADIATION-INDUCED EFFECTS ON HUMAN PRIMARY THYROID CELL PROLIFERATION

Kostic I.¹, Toffoletto B.³, Toller M.², Moretti M.², Beltrami C.A.³, Ambesi Impiombato F.S.², Curcio F.², ¹Institute of Pathophysiology, School of Medicine, Kragujevac, Serbia, ²Dipartimento di Patologia e Medicina Sperimentale e Clinica, Università degli Studi di Udine, Italy, ³Dipartimento Scienze Morfologiche, sez. di Anatomia Patologica, Università degli Studi di Udine, Italy

P066 EXTERNAL HYDROGEN PEROXIDE IS INDISPENSIBLE FOR EXPERIMENTAL INDUCTION OF LIPID PEROXIDATION VIA FENTON REACTION IN PORCINE THYROID HOMOGENATES

Karbownik-Lewinska M.^{1,3}, Stepniak J.¹, Szosland J.^{1,3}, Zasada K.^{1,3}, Lewinski A.^{2,3}

¹Department of Oncological Endocrinology, Medical University of Lodz, Lodz, Poland, ²Chair and Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland, ³Polish Mothers Memorial Hospital - Research Institute, Lodz, Poland

P067 DIFFERENT IN VITRO ACTIVITIES OF SPORADIC, FAMILIAR AND SOMATIC TSH-RECEPTOR (TSHR) MUTATIONS

Lueblinghoff J.¹, Mueller S.¹, Jaeschke H.¹, Eszlinger M.¹, Berger H.², Paschke R.¹ ¹III Medical Department, University of Leipzig, Leipzig, Germany, ²IMISE, University of Leipzig, Leipzig, Germany

Poster Discussion 7 Thyroid cancer 2 Chairperson: Rosella Elisei (Pisa, Italy)

P068 RETINOIC ACID RECEPTOR AND RETINOID X RECEPTOR EXPRESSION AS A DIAGNOSTIC PARAMETER FOR THE DIFFERENTIAL DIAGNOSIS OF WELL-DIFFERENTIATED THYROID CARCINOMA

<u>Smit J.W.</u>, Hoftijzer H.C.L., Morreau Y.Y., Corssmit H., Romijn P.M.E., Johannes A. Department of Endocrinology and Metabolism, Leiden University medical Center, Leiden, The Netherlands

P069 OVEREXPRESSIONOFNrCAMINPAPILLARYTHYROIDCARCINOMAISASSOCIATEDWITHUPREGULATION OF THE β-CATENIN AND CYCLIN D1 GENES AND ABERRANT β-CATENIN LOCALIZATION

Gorka B.¹, Skubis-Zegadlo J.¹, Mikula M.², Przytula E.³, Sygut J.⁴, Czarnocka B.¹ ¹Department of Clinical Biochemistry and Molecular Biology, Warsaw, Poland, ²Department of Gastroenterology and Hepatology Warsaw, Poland, ³Department of Pathology, Medical Centre for Postgraduate Education, Warsaw, Poland ⁴Department of Pathology, Swietokrzyskie Oncology Centre, Kielce, Poland

P070 INCREASED PERCENTAGE OF MICROVESSELS BUT DECREASED DENSITY OF LARGE VESSELS IN PAPILLARY CARCINOMAS AS COMPARED TO HOT AND COLD THYROID NODULES

Sancak S.^{1, 4}, Hardt A.¹, Ricken A.², Hentschel B.³, Lorenz S.¹, Eszlinger M.¹, Sen L.S.⁵, Gulluoglu B.M.⁵, Sever Z.⁶, Eren F. T.⁶, Akalin N.S.⁴, Paschke R.¹



¹3rd Medical Department, Leipzig University,Leipzig,Germany, ²Institute of Anatomy, Leipzig, Germany, ³ IMISE Leipzig University,Leipzig,Germany, ⁴ Section of Endocrinology and Metabolism of Marmara Medical School, Istanbul, Turkey, ⁵General Surgery Department of Marmara Medical School, Istanbul, Turkey, ⁶Department of Pathology of Marmara Medical School, Istanbul, Turkey

P071 THE mTOR EFFECTOR EUKARYOTIC INITIATING FACTOR 4E (eIF4E) IS OVEREXPRESSED IN THYROID CANCER AND CORRELATES WITH TUMOR AGGRESSIVENESS

Kouvaraki M.², Rassidakis G. Z.¹, Staikou E.¹, Moraitis D.¹, Patsouris E.¹, **<u>Tseleni-Balafouta S.</u>¹** ¹1st Department of Pathology, University of Athens, Greece, ²Department of Surgery, University of Larissa, Greece

P072 PRIMARYANAPLASTICTHYROIDCANCERCELLSOBTAINEDBYFINE-NEEDLEASPIRATIONCYTOLOGY: ANTIPROLIFERATIVE EFFECTS OF CHEMOTHERAPEUTIC AGENTS OR THIAZOLIDINEDIONES

Antonelli A.¹, Ferrari S.M.¹, Fallahi P.¹, Berti P.², Materazzi G.², Marchetti I.³, Ugolini C.², Basolo F.², Miccoli P.², Ferrannini E.¹

¹Department of Internal Medicine, University of Pisa; Pisa; Italy, ²Department of Surgery, University of Pisa; Pisa; Italy, ³Section of Cytopathology, Division of Surgical, Molecular and Ultrastructural Pathology, University Hospital of Pisa; Pisa, Italy

P073 IDENTIFYING SPECIFIC FUNCTIONAL PROFILES OF THYROID TUMOURS FROM THE FOLLICULAR THYROID EPITHELIA

Montero-Conde C.¹, Giménez G.², Combalía N.³ Leskela S.¹, Landa I.¹, López-Jiménez E.¹, Leandro L.J.¹, Matías-Guiu X.⁴, Mauricio D.⁵, Robledo M.^{1,6}

¹Hereditary Endocrine Cancer Group, Spanish National Cancer Centre (CNIO), Madrid, Spain, ²Endocrinology Unit, Hospital of Sabadell, Spain, ³Pathology Service, Hospital of Sabadell, Spain, ⁴Department of Pathology and Molecular Genetics, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain, ⁵Department of Endocrinology, Arnau de Vilanova Hospital (IRBLLEIDA), Lleida, Spain, ⁶ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Valencia, Spain

P074 KARYOMETRIC FEATURES OF CELL NUCLEI IN PAPILLARY THYROID CANCER AND THEIR CORRELATES IN GENE EXPRESSION PROFILE

<u>Chekan M.</u>¹, Swierniak M.¹, Jarzab M.³, Oczko-Wojciechowska M.¹, Rusinek D.¹, Snietura M.², Chmielik E.², Smok-Ragankiewicz A.², Lange D.², Jarzab B.¹

¹Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Branch Gliwice, Gliwice, Poland, ²Tumor Pathology Departament, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Branch Gliwice, Gliwice, Poland, ³Tumor Biology Department, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Branch Gliwice, Gliwice, Poland

P075 IMMUNOHISTOCHEMICAL EXPRESSION OF GALECTIN-3, FIBRONECTIN, CYTOKERATIN-19 AND HBME1 IN BENIGN AND MALIGNANT THYROID NODULES

Siderova M.¹, Hristozov K.¹, Krasnaliev I.², Softova E.²

¹Clinic of Endocrinology, University Hospital "St. Marina", Varna, Bulgaria, ²Department of Pathology, University Hospital "St. Marina", Varna, Bulgaria

P076 WT1 PROTEIN IN THE THYROID GLAND: AN IMMUNOHISTOCHEMICAL ANALYSIS OF CYTOPLASMIC STAINING USING THE MONOCLONAL ANTIBODY 6F-H2

<u>Colato C.</u>¹, Gobbato M.¹, Brazzarola P.², Davì M. V.³, Francia G.³, Ambrosetti M. C.⁴, Dardano A.⁵, Monzani F.⁵, Chilosi M.¹, Ferdeghini M.⁴

¹Dipartimento di Patologia Universita of Verona, Verona Italy, ²Scienze Chirurgiche e Gastroenterologiche Universita di Verona, Verona Italy, ³Dipartimento di Scienze Biomediche e Chirurgiche Universita di Verona, Verona Italy, ⁴Dipartimento di Scienze Morfologico-Biomediche Universita di Verona, Verona Italy, ⁵Dipartimento di Medicina Interna Universita di Pisa, Pisa Italy



P077 MUTATIONAL ANALYSIS OF THE Braf and Met GENES IN GREEK PATIENTS WITH PAPILLARY THYROID CARCINOMA

Litsiou E.¹, Fanourakis G.¹, Mitsiades N.², Voutsinas G.³, Sozopoulos E.¹, Karga E.⁴, Patsouris E.¹, **<u>Tseleni-</u>** Balafouta S.¹

¹1st Department of Pathology, Medical School, University of Athens, Athens, Greece, ²Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, ³Laboratory of Environmental Mutagenesis and Carcinogenesis, Institute of Biology, NCSR "Demokritos", Athens, Greece, ⁴2nd Division of Endocrinology, Alexandra Hospital, Athens, Greece

P078 CLAUDIN-1 IMMUNOHISTOCHEMICAL EXPRESSION IN PAPILLARY THYROID CARCINOMA: A CANDIDATE MARKER?

<u>Colato C.</u>¹, Gobbato M.¹, Brazzarola P.², Davi M.V.³, Francia G.³, Ambrosetti M. C.⁴, Dardano A.⁵, Monzani F.⁵, Chilosi M.¹, Ferdeghini M.⁴

¹Dipartimento di Patologia, Università di Verona, Verona, Italy, ²Dipartimento di Scienze Chirurgiche e Gastroenterologiche, Università di Verona, Verona, Italy, ³Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Verona, Italy, ⁴Dipartimento di Scienze Morfologico-Biomediche, Università di Verona, Verona, Italy, ⁵Dipartimento di Medicina Interna, Università di Pisa, Pisa, Italy

P079 MALIGNANT PROPERTIES ASSOCIATED TO PAX8 RE-EXPRESSION

<u>**Ruiz-Llorente S.**</u>¹, Martin-Duque P.², Santisteban P.¹ ¹Instituto de Investigaciones Biomedicas, Madrid, Spain, ²Universidad Francisco de Vitoria, Spain

Poster Discussion 8 Autoimmune thyroid disease Chairperson: Elias Efthimiou (Thessaloniki, Greece)

P080 INTERACTION OF TIME ON SELENIUM INDUCED REDUCTION OF ANTI-TPO CONCENTRATIONS IN PATIENTS WITH AUTOIMMUNE THYROIDITIS

Duntas L.¹, Boutsiadis A.¹, Loukari E.¹, Mantzou E.¹, Pitsouni E.² ¹Endocrine Unit, Evgenidion Hospital, University of Athens, Greece, ²Biomedical Laboratory, Evgenidion Hospital, University of Athens, Greece

P081 ROLE OF DIETARY SELENIUM SUPPLEMENTATION IN INFLUENCING THE NATURAL COURSE OF AUTOIMMUNE THYROIDITIS

<u>Nacamulli D.</u>, Petricca D., Mian C., Girelli M. E., Mantero F., Betterle C. Endocrinology Unit, Department of Medical & Surgical Sciences, University of Padua, Padua, Italy

P082 D0 THYROID AUTOIMMUNITY AND DYSFUNCTION MODIFY CLINICAL OUTCOME OF MULTIPLE SCLEROSIS (MS) PATIENTS RECEIVING IFN-ß?

Dardano A.¹, Manfredonia F.², Pasquali L.², Polini A.¹, Tognini S.¹, Iudice A.², Monzani F.¹ ¹Internal Medicine, University of Pisa, Pisa, Italy, ²Neuroscience, University of Pisa, Pisa, Italy

P083 MEASUREMENT OF IL-18, IL-10, IL-15 AND TRANSFORMING GROWTH FACTOR ETA 1 IN SERA OF PATIENTS WITH HASHIMOTOS THYROIDITIS

Gerenova J.¹, Manolova I.²

¹Department of Internal Medicine, Section of Endocrinology, Medical Faculty, Trakia University, Stara Zagora, Bulgaria, ²Laboratory of Clinical Immunology, University Hospital, Medical Faculty, Trakia University, Stara Zagora, Bulgaria

P084 DUAL RESPONSE IN THYROID ANTIBODIES TO DIFFERENT IODINE INTAKE LEVELS AMONGTHE OLD - A COMPARATIVE POPULATION BASED STUDY

Andersen S., Iversen F., Terpling S., Pedersen M. S., Gustenhoff P., Laurberg P. Skagen Hospital and Aalborg Hospital, Arhus University Hospital, Denmark



P085 COURSE OF CHRONIC AUTOIMMUNE THYROIDITIS (AIT) IN ADULTS

Altun R., <u>Erdogan M. F.</u>, Demir Ö., Güllü S., Kamel N. Endocrinology and Metabolic Diseases Department, Ankara University Faculty of Medicine, Ibni Sina Hospital, Ankara, Turkey

P086 PREVALENCE OF AUTOIMMUNE GASTRITIS AND VITAMIN B12 DEFICIENCY IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE

<u>Savic S.</u>, Zarkovic M., Ciric J., Beleslin B., Stojkovic M., Trbojevic B. Institute of Endocrinology, Clinical Centre of Serbia, Belgrade, Serbia

P087 TAb PREVALENCE IN DIFFERENT TOWNS IN THE SAME ITALIAN REGION

De Remigia A.¹, Lattanzio M. F.², De Laurentis B.², Matera S.², De Remigis P.¹, Vianale L.¹ ¹Endocrine Unit, General Hospital, Chieti Italy, ²Clinical Pathology, General Hospital, Chieti Italy

P088 CHRONIC C HEPATITIS TREATMENT WITH α-INTERFERON AND THYROID DISFUNCTION Zantut-Wittmann D. E.¹, Pavan M. H.², Pavin E. J.¹, Goncales F.²

¹Endocrinology Division, School of Medical Sciences, State University of Campinas, Campinas, ²Infectious Diseases Division, School of Medical Sciences, State University of Campinas, Sao Paolo, Brasil

P089 THE ROLE OF THYROID DOPPLER ULTRASONOGRAPHY IN EARLY PREDICTION OF GRAVES' DISEASE COURSE <u>Zaletel K.</u>, Gaberscek S., Pirnat E., Hojker S.

University Medical Centre, department of Nuclear medicine, Ljubljana, Slovenia

P090 HIGH PREVALENCE OF PAINLESS THYROIDITIS DURING THE CLINICAL COURSE OF GRAVES HYPERTHYROIDISM

<u>Okamura K.</u>, Bandai S., Fujikawa M., Sato K., Iida M. 2nd Dept. Int. Med, Kyushu University, Fukuoka, Japan

P091 IODINE CONTENT IN THYROID TISSUE FROM GRAVES PATIENTS TREATED WITH SURGERY AND PRE-TREATED WITH EITHER STABLE IODINE OR THE THYROSTATIC DRUG PROPYLTIOURACIL

Hansson M.¹, Berg G.², Grunditz T.³, Jansson S.⁴, Lausmaa J.⁵

¹Department of Radiation Physics, Göteborg University, Gothenburg, Sweden, ²Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden, ³Department of Otolaryngology, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁴Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Department of Chemistry and Materials Technology, SP Technical Research Institute of Sweden, Sweden

P092 TAMOXIFEN, CICLOSPORINE : NEW THERAPEUTIC APPROACHES IN RIEDEL'S THYROIDITIS <u>**Perimenis P.**</u>¹, Proust-Lemoine E.¹, Gernez-Lestradet C.², Marcelli S.¹, Wémeau J.L.¹

Perimenis P., ', Proust-Lemoine E.', Gernez-Lestradet C.², Marcelli S.', Wémeau J.L. ¹Endocrinology, Chru, Lille, France, ²Endocrinology, Dole, France

P093 DIAGNOSTIC AND THERAPEUTICAL ASPECTS IN THYROID AUTOIMMUNE DISEASE AND CHRONIC URTICARIA -CASE REPORTS

Musat M.¹, Bumbacea R.¹, Grigoras E.²

¹Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, ²Institute of Endocrinology C.I.Parhon, Bucharest, Romania, ²Dept. of Dermatology, Elias University Hospital Bucharest, Romania

Poster Discussion 9

Goitre 2

Chairperson: Istvan Szabolcs (Budapest, Hungary)

P094 RAPID (ON SITE) INTERPRETATION FNA VERSUS NON-RAPID INTERPRETATION FNA BIOPSIES IN THYROIDAL LESIONS

Oikonomou V., **Koniaris E.,** Fotou M., Drouveli Th., Kotzia E. Department of Clinical Cytology, "Hippokratio" General Hospital, Athens, Greece



P095 THE ROLE OF SONOGRAPHIC-CYTOLOGIC CORRELATION FOR SELECTING REASPIRATED NODULES TO REDUCE THE FALSE-NEGATIVE RATE OF ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION BIOPSY

Kwak J. Y., Kim E. K.

Radiology, Yonsei University Yonsei College of Medicine, Seoul, South Korea

- P096 POSITIVE PREDICTIVE VALUES OF SONOGRAPHIC FEATURES OF SOLID THYROID NODULE Son E. J., Kim E. K., Kwak J. Y., Hong S. W., Chang H. S. Yonsei University, College of Medicine, Seoul, Korea
- P097 DIAGNOSISOF WIDELY-INVASIVE FOLLICULAR THYROID CARCINOMA BYSONOGRAPHY: CORRELATION WITH HISTOPATHOLOGIC RESULTS

Shin J. H.¹, Yoo E. Y.¹, Han B. K.¹, Ko E. Y.¹, Oh Y. L.² ¹Radiology,Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, South Korea, ²Pathology,Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, South Korea

P098 THYROID CANCER PREVALENCE IN 3351 CONSECUTIVE FINE NEEDLE BIOPSY ASPIRATION SPECIMEN

Taccaliti A.¹, Palmonella G.¹, Silvetti F.¹, Gusella P.², Boscaro M.¹

¹Medicina Interna e biotecnologie applicate, Clinica di Endocrinologia Ospedali Riuniti, Ancona, Italia, ²Servizi, UO Citopatologia diagnostica Ospedali Riuniti, Ancona, Italia

P099 THYROID NODULES SMALLER THAN 5 MM IN MAXIMUM DIAMETER: ASSESSING THE EFFICACY OF US-FNAB AND THE PATHOLOGY RESULTS

Kim D. W.¹, Park A. W.¹, Kim S. H.², Kim T. H.², Lee S. H.², Rho M. H.³

¹Department of Radiology, Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea., ²Department of General Surgery Thyroid & Breast Clinic, Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea, ³Department of Radiology, Masan Samsung Hospital, Sungkyunkwan University School of Medicine, South Korea

P100 FNAB OF SMALL THYROID NODULES IN AREA OF RECENTLY NORMALIZED IODINE SUPPLY

Slowinska-Klencka D.¹, Popowicz B.¹, Lewinski A.², Sporny S.³, Klencki M.¹

¹Department of Morphometry of Endocrine Glands, Chair of Endocrinology and Metabolic Diseases, Medical University of Lodz, ²Clinic of Endocrinology and Metabolic Diseases, Chair of Endocrinology and Metabolic Diseases, Medical University of Lodz, ³Department of Dental Patomorphology, Chair of Patomorphology, Medical University of Lodz

P101 MULTINUCLEATED GIANT CELLS IN FINE NEEDLE ASPIRATES. CAN THEY HELP DIFFERENTIATE PAPILLARY THYROID CANCER FROM BENIGN NODULAR GOITER?

Rizouli K. A., Rizoulis A. A., Antonakopoulos G. N. Department of Histology and Embryology, University of Thesally, Larissa, Greece

P102 PARTIAL STERNOTOMY FOR MEDIASTINAL THYROID PATHOLOGY <u>Markogiannakis H.</u>, Fleming B. Department of Endocrine Surgery, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom

P103 THE ROLE OF ULTRASOUND AND FROZEN SECTION IN SURGICAL MANAGEMENT OF THYROID NODULES WITH SUSPICIOUS FOR PAPILLARY THYROID CARCINOMA ON ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION BIOPSY

Moon H.J., Kwak J.Y., Kim E.K., Kim M.J. Department of Diagnostic Radiology, Yonsei University College of Medicine, Seoul, South Korea N



P104 INCIDENTAL PARATHYROIDECTOMY DURING TOTAL THYROIDECTOMY: INCIDENCE, CLINICAL CONSEQUENCES AND RISK FACTORS

Lagoudianakis E., **Michalopoulos N.**, Markogiannakis H., Pararas N., Papanikolaou D., Tsekouras D., Papadima A., Alevizos L., Katergiannakis V., Manouras A.

Department of Endocrine Surgery, 1st Department of Propaedeutic Surgery, Hippokrateion Hospital, Athens

P105 TOTAL THYROIDECTOMY: ELECTROTHERMAL BIPOLAR VESSEL SEALER, HARMONIC SCALPEL OR CLASSIC SUTURE-LIGATION TECHNIQUE?

<u>Kekis P.</u>, Markogiannakis H., Lagoudianakis E., Pararas N., Alevizos L., Antonakis P., Tsekouras D., Giannopoulos A., Papadima A., Manouras A.

Department of Endocrine Surgery, 1st Department of Propaedeutic Surgery, Hippokrateion Hospital, Athens

P106 BREAST CANCER (BC) AND BENIGN THYROID DISORDERS (BTD)

<u>Giustarini E.</u>, Muller I., Fiore E., Pinchera A., Giani C. Department of Endocrinology, University of Pisa, Pisa, Italy

P107 GRANULAR CELLS TUMOUR LOCALISED IN THE THYROID LOGE AND DIAGNOSED BY CYTOLOGIE

<u>Monpeyssen H.</u>¹, Voillemot N.², Tramalloni J.¹, Klijanienko J.², Correas J.M.¹ Helenon O.¹ ¹Radiologie adulte, Hopital Necker, Paris, France, ²Anatomopathologie Institut Curie. Paris, France

Poster Discussion 10

Clinical thyroidology 2 & pregnancy Chairperson: Jean-Lewis Wemeau (Lille, France)

P108 INFLUENCE OF ACEI ON THE LEVEL OF VON WILLEBRAND FACTOR IN THYROTOXICOSIS

Babenko A.¹, Grineva E.², Kadinskaja M.³

¹Petersburg Research Institute of Cardiology, Saint-Petersburg, Russia, ²Chair Department of Internal Medicine N 1, Saint-Petersburg Medical State University after named Pavlov, Saint-Petersburg, Russia, ³Department of laboratory diagnostic, State University after named Pavlov, Saint-Petersburg. Russia

P109 PLASMA TOTAL AND ACYLATED GHRELIN CONCENTRATIONS IN CLINICAL AND SUBCLINICAL THYROID DYSFUNCTION

Tanda M. L.¹, Lombardi V.¹, Genovesi M.², Ultimieri F.², Lai A.¹, Gandolfo M.¹, Grasso L.², Ghigo E.³, Martino E.², Bartalena L.¹

¹Department of Clinical Medicine, Section of Endocrinology, University of Insubria, Varese, Italy, ²Department of Endocrinology and Metabolism, Section of Endocrinology, University of Pisa, Pisa, Italy, ³Department of Internal Medicine, Section of Endocrinology, University of Turin, Turin, Italy

P110 OSTOPROTEGERIN AND SPONTANEOUS COURSE OF SUBCLINICAL HYPOTHYROIDISM

Shinkov A.¹, Atanassova I.¹, Borissova A. M.¹, Kovatcheva R.¹, Aslanova N.¹, Vlahov J.¹, Vukov M.² ¹University Hospital of Endocrinology, Medical University, Sofia, ²National Center of Health Information, Medical University – Sofia

P111 EOTAXIN AND VISFATIN LEVELS AND THEIR CORRELATION WITH SOMATOMETRIC PARAMETERS IN HYPER- AND HYPOTHYROIDISM BEFORE AND AFTER TREATMENT

Pontikides N.¹, Papadopoulou F.¹, Dumas A.², Bougoulia M.¹, Tziomalos K.¹, Krassas G. E.¹ ¹Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece, ²3rd of Department of Nuclear Medicine, Aristotle University, Papageorgiou Hospital, Thessaloniki, Greece



P112 THYROID STUNNING IN HYPERTHYROID PATIENTS

Lundh C.¹, Lindencrona U.¹, Himmelman J.¹, Lundström A.¹, Berg G.², Forssell-Aronsson E.¹ ¹Dept. of Radiation Physics, University of Gothenburg, Göteborg, Sweden, ²Dept. of Oncology, University of Gothenburg, Göteborg, Sweden

P113 ANNUAL VARIATION OF THYROID FUNCTION ACCORDING TO SEASONS AND ULTRAVIOLET RADIATION CHANGES

<u>Tsekouras A.</u>¹, Saltamavros A.², Mylonas P.¹, Lampropoulou E.¹, Argyriou A.³, Georgopoulos N. A.⁴, Vagenakis A. G.¹, Markou K. B.¹

¹Division of Endocrinology, Department of Internal Medicine, University of Patras Medical School, University Hospital, Patras, Greece, ²Transfusion Center, St. Andrews General Hospital of Patras, Greece, ³Laboratory of Atmospheric Physics, Department of Physics, University of Patras, Greece, ⁴Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, University of Patras Medical School, University Hospital, Patras, Greece

P114 SERUM SELENIUM AND THYROID STATUS IN A COHORT OF PREGNANT WOMEN WITH SUFFICIENT IODINE SUPPLEMENTATION

Lozanov B.¹, Tzachev K.², Kirilov G.¹, Atzeva E.³, Vukov M.³ ¹Clinical Center of Endocrinology, Sofia, Bulgaria, ²Dpt Clin. Laboratory & Immunology, MU, Sofia, Bulgaria, ³National Center of Promotion of Public Health

P115 MATERNAL AUTOIMMUNE THYROID DISEASE (ATD) AND THE FETAL IMMUNE SYSTEM

Oderup C.¹, Svensson J.², Akesson Ch.¹, Holm B.¹, Lantz M.³, <u>Hallengren B.³</u>, Ericsson U. B.³, Arvastsson J.¹, Danska J.⁴, Cilio C.¹

¹Cellular Autoimmunity Unit, Department of Clinical Sciences, Malmö University Hospital, Malmö, Sweden, ²Department of Pediatrics, Malmö University Hospital, Malmö, Sweden, ³Department of Endocrinology, Malmö University Hospital, Malmö, Sweden, ⁴Department of Immunology, Faculty of Medicine University of Toronto, Toronto, Canada

P116 THYROID AUTOIMMUNE DISORDERS-EVOLUTION OF THYROID FUNCTION IN PREGNANT WOMEN Virtej I.¹, Vartej P.², Fica S.³, Zervoudis S.⁴

¹Endocrine Department, University of Medicine "Carol Davila" Bucharest, Romania and Endocrine Private Practice Trikala, Greece, ²Department of Obstetrics-Gynecology, University of Medicine "Carol Davila" Bucharest, Romania, ³Department of Endocrinology, University of Medicine "Carol Davila" Bucharest, Romania, ⁴Department of Gynecology, LITO Maternity Hospital Athens, Greece, University of Medicine "Carol Davila" Bucharest, Romania

P117 EVALUATION OF THYROID DYSFUNCTION IN THE POSTPARTUM PERIOD BY COLOUR FLOW DOPPLER SONOGRAPHY

<u>Gaberscek S.</u>, Osolnik J., Zaletel K., Pirnat E., Hojker S. Department of Nuclear Medicine, University Medical Centre Ljubljana, Slovenia

P118 NEONATAL HYPOTHYROIDISM (STUDY BY THE KASTORIA HOSPITAL)

Passalidou I., Hassios M., Karapavlidou P., Outas A., Oplopiadis D., Sotiriou O. Immunology Laboratory, General Hospital of Kastoria

P119 EPIDEMIOLOGICAL STUDY OF THYROID FUNCTION IN A SAMPLE OF GENERAL POPULATION OF KASTORIA PROVINCE DURING A 3-YEAR PERIOD

<u>Karapavlidou P</u>., Passalidou I., Hasios M., Oplopiadis D., Sotiriou O Immunology laboratory, General Hospital of Kastoria, Greece 21



Olympic Hall I

14:00-14:50	The European Thyroid Association Harington-De Visscher Prize Lecture Gene expression in normal and tumor thyroid cells and tissues Carine Maenhaut (Brussesls, Belgium)
15:00-15:45	Meet the Experts 5 Live imaging of follicle function Davide Calebiro (Milan, Italy)
Olympic Ha	
15:00-15:45	Clinical case discussions – Subclinical thyroid disease Chairpersons and discussants: Leonidas Duntas (Athens, Greece) Bernadette Biondi (Naples, Italy)
16:00	Departure for the excursion (page 54)



Tuesday, September 23rd, 2008

Olympic Hall I

- 06:45-07:15 Breakfast (Olympic Hall Foyer)
- 07:15-08:30 Satellite Symposium (ASTRA ZENECA) Taking aim: targeted therapies in medullary thyroid cancer Chairperson: Samuel Wells (St. Louis, USA) Martin Schlumberger (Paris, France)

Introduction Samuel Wells (St. Louis, USA)

Targeting oncogenic pathways for medullary thyroid cancer therapy Masssimo Santoro (Naples, Italy)

Design and conduct of clinical trials for targeted agents in medullary thyroid cancer Martin Schlumberger (Paris, France)

Clinical development of vandetanib in medullary thyroid cancer Samuel Wells (St. Louis, USA)

Concluding remarks Martin Schlumberger (Paris, France)

- 08:30-10:30 Oral session 4 Iodine and thyroid hormones Chairpersons: Andrzej Lewinsky (Lodz, Poland) Konstantinos Markou (Patra, Greece)
- 031 BIOLOGICAL VARIATION OF SERUM TSH, FREE T4 AND FREE T3 DURING A 10 YEAR PERIOD IN INDIVIDUALS WITHOUT THYROID DISEASE

Jensen E.¹, Blaabjerg O.¹, Hyltoft Petersen P.², Abrahamsen B.³, Brixen K.³, Hegedüs L.³ ¹Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark,²NOKLUS, Norwegian quality improvement of primary care laboratories, Division for General Practice, University of Bergen, Bergen, Norway,³Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

032 THE ROLE OF TRBETA IN ACUTE ILLNESS-INDUCED ALTERATIONS IN HYPOTHALAMIC TRH, TYPE 2 DEIODINASE (D2) AND TYPE 3 DEIODINASE (D3) MRNA EXPRESSION

Boelen A.¹, Kwakkel J.¹, Chassande O.², Fliers E.¹

¹Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands, ²Université Victor Segalen, Bordeaux, France

033 EFFECTS OF LONG TERM IODINE INTERVENTION PROGRAM ON THE INDICATORS OF IODINE SUFFICIENCY

Mirmiran P., Salarkia N., Hedayati M., **Azizi F.**

Endocrine Research Center, National Nutrition and Food Technology Research Institute, Shaheed Beheshti University and Medical Services, Tehran, Iran

034 HORMONAL REGULATION OF IODIDE UPTAKE IN PLACENTAL PRIMARY CULTURES

Burns R.¹, Smith D. F.¹, O'Herlihy C.², Smyth P. PA.¹ ¹UCD Conway Institute, UCD, Belfield, Dublin, Ireland, ²National Maternity Hospital, Dublin, Ireland 2



035 IN PENDRED'S SYNDROME, LOSS OF THYROID IODINATION IS ASSOCIATED WITH MISLOCALIZATION AND UPREGULATION OF PROTEINS INVOLVED IN IODINE METABOLISM AND WITH CELL TOXICITY: A MORPHOLOGICAL STUDY

Senou M.¹, Khalifa C.¹, Timmesch M.¹, Van Sande J.², Dumont J.², Audinot J.N.³, <u>Many M.C.¹</u> ¹Laboratoire de Morphologie Expérimentale, UCL, Brussels, Belgium, ²IRIBHM, ULB, Brussels, Belgium,³Laboratoire d analyse des matériaux, CRP G. Lippmann, Luxembourg

036 EFFECTS OF SELENIUM AND IODINE DEPLETION / REPLETION ON BEHAVIORS OF ADULT C57BL/6MICE

Li J.^{1,2}, Peters J.P.¹, Houbeau G.¹, Bister J.-L.³, Rivera M.T.⁴, Vanderpas J.^{1,4}, Huynen M.C.⁵, Wolff F.⁶, Mercier M.¹

¹Departments of Psychology, ²Department of Radiation Medicine, Faculty of Preventive Medicine, The Fourth Military Medical University, Xi'an, P.R.China, ³Laboratory of Animal Physiology, ⁴Unit of Epidemiology, University of Namur, Namur, Belgium, ⁵Behavioural Biology Unit, Department of Environmental Sciences, Institute of Zoology, University of Liege, 22 Quai Van Beneden, Liege, Belgium, ⁶Department of Chemistry, University Hospital Brugmann, Brussels, Belgium

037 NOVEL PHYSIOLOGICAL IMPLICATIONS OF CO-TRANSPORT OF (SULFATED) IODOTHYRONINES AND TAUROCHOLATE BY LIVER SLC10A1

Visser W.E.¹, Wong W.S.¹, Friesema E.C.H.¹, Geyer J.², Visser T.J.¹

¹Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, ²Institute of Pharmacology and Toxicology, Justus-Liebig-University of Giessen, Giessen, Germany

038 DISTURBED ALTERNATIVE SPLICING OF TYPE 1 DEIODINASE IN RENAL CANCER: POTENTIAL ROLE OF SPLICING FACTORS SF2/ASF AND HNRNPA1

<u>Piekielko-Witkowska A.</u>¹, Master A.¹, Wojcicka A.¹, Lampkowska J.¹, Poplawski P.¹, Brozda I.¹, Tanski Z.², Nauman A.¹

¹Medical Center of Postgraduate Education, Department of Biochemistry and Molecular Biology, ul Warsaw, Poland, ²Specialistic Hospital, Ostroleka, Poland

Olympic Hall III)

08:30-10:30 Oral session 5

Clinical thyroidology

Chairpersons: Jacques Orgiazzi (Pierre-Benite, France) Neoklis Georgopoulos (Patra, Greece)

039 ASSOCIATION OF THYROID FUNCTION WITH MEASURES OF ADIPOSITY AND METABOLIC PROFILE IN APPARENTLY HEALTHY INDIVIDUALS

<u>Saltiki K.</u>¹, Voidonikola P.², Mantzou E.³, Stamatelopoulos K.², Papamichael C.², Alevizaki M.¹

¹Endocrine Unit, Dept Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine,²Vascular Laboratory, Dept of Medical Therapeutics, Alexandra Hospital, Athens University School of Medicine,³Endocrine Unit, Evgenidion Hospital, Athens University School of Medicine

040 THYROID DYSFUNCTION, AGING AND CARDIOVASCULAR RISK

Borissova A.M., Kovatcheva R., **Shinkov A.**, Atanassova A., Vlahov J., Aslanova N., Dakovska L., Vukov M. University Hospital of Endocrinology, National Center of Medical Information, Medical University Sofia, Bulgaria



041 HYPOTHYROIDISM HAS AN ADVERSE EFFECT ON HUMAN SPERMATOGENESIS: A PROSPECTIVE, CONTROLLED STUDY

Krassas G. E.¹, Pontikides N.¹, Papadopoulou F.¹, Tziomalos K.¹, Zeginiadou T.¹, Hammadeh M.²

¹Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece,²Department of Obstetrics and Gynaecology, University of Saarland, Homburg Saar, Germany

042 NO LINK BETWEEN X CHROMOSOME INACTIVATION PATTERN AND SIMPLE GOITRE IN FEMALES. EVIDENCE FROM A TWIN STUDY

Brix T.¹, Hansen P.², Knudsen G.³, Kringen M. K.³, Kyvik K. O.², Sorensen THIA.⁴, Orstavik K. H.⁵, Hegedüs L.¹ ¹Department of Endocrinology and Metabolism, Odense University Hospital,Odense, Denmark,²The Danish Twin Registry, University of Southern Denmark, Odense, Denmark, ³Faculty Division Rikshospitalet, University of Oslo, Oslo, Norway, ⁴Danish Epidemiology Science Centre, Institute of Preventive Medicine, Copenhagen University Hospital, Copenhagen, Denmark, ⁵Department of Medical Genetics, Rikshospitalet University Hospital, Oslo, Norway

043 US-GUIDED PERCUTANEOUS RADIOFREQUENCY THERMAL ABLATION FOR THE TREATMENT OF SOLID BENIGN HYPERFUNCTIONING OR COMPRESSIVE THYROID NODULES

Deandrea M.¹, Limone P.¹, Basso E.¹, Mormile A.¹, Ragazzoni F.¹, Gamarra E¹., Spiezia S.², Faggiano A.³, Colao A.³, Molinari F.⁴, Garberoglio R.¹

¹Endocrinology Section, A.S.O. Ordine Mauriziano di Torino, "Umberto I" Hospital, Turin; ²Department of Surgery, Ultrasound Guided & Neck Pathologies Surgery Unit, "S. Maria del Popolo e degli Incurabili" Hospital, A.S.L. NA1, Naples; ³Department of Clinical and Molecular Endocrinology and Oncology, "Federico II" University of Naples, Naples; ⁴Department of Electronics, Polytechnic of Turin, Turin, Italy

044 RADIOFREQUENCY THERMAL ABLATION IN THE TREATMENT OF THYROID NODULES: 2 YEAR FOLLOW-UP

Spiezia S.¹, Faggiano A.², Ramundo V.², Garberoglio R.³, Caiazzo C.¹, Assanti A. P.¹, Deandrea M.³, Limone P. P.³, Lombardi G.², Colao A.²

¹Unit of Ultrasound Guided & Neck Pathology Surgery, "S. Maria del Popolo degli Incurabili" Hospital, Naples, Italy,²Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" University of Naples, Italy,³Unit of Endocrinology and Ultrasound, Mauriziano Hospital, Turin, Italy

045 INFLUENCE OF THE INTERVAL (24, 48, OR 72 HOURS) BETWEEN THE ADMINISTRATION OF 0.1 MG RECOMBINANT HUMAN THYROTROPIN (RHTSH) AND SUBSEQUENT THYROID RADIOIODINE UPTAKE IN NONTOXIC GOITER PATIENTS. EVALUATION BY A RANDOMIZED DOUBLE-BLINDED TRIAL Fast S.¹, Grupe P.², Bonnema S. J.¹, Hegedüs L.¹

¹Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark, ²Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark

046 SEASONAL VARIATION OF URINARY IODINE IN PREGNANT IRISH WOMEN <u>Smyth P.</u>¹, Burns¹, Smith¹, O' Herlihy²

¹UCD Conway Institute, UCD, Belfield, Dublin, Ireland ²National Maternity Hospital, Dublin, Ireland PZ

21



Saturday
$ \rightarrow $
Sunday 21
Monday 22
Tuesday 23
eday 24

Olympic Hall II

10:30-11:00 Coffee Break

Olympic Hall III

11:00-12:30 Symposium 6 (Clinical) Graves' orbitopathy: Present and future Chairpersons: George J. Kahaly (Mainz, Germany) Nikolaos Pontikides (Thessaloniki, Greece)

Recent developments in our understanding of GO pathogenesis Wilmar Wiersinga (Amsterdam, The Netherlands)

Novel treatments on the horizon GO Mario Salvi (Milan, Italy)

What treatment for hyperthyroidism if GO is present? Claudio Marcocci (Pisa, Italy)

Olympic Hall I

11:00-12:30 Symposium 7 (Basic) Thyroid remodelling and fibrosis (Hashimoto's thyroiditis) Chairpersons: Ase Krogh Rasmussen (Copenhagen, Denmark) Agathoklis Tsatsoulis (Ioannina, Greece)

Cytokines, chemokines and thyroid remodeling Rosa Marina Melillo (Naples, Italy)

The role of growth factors on apoptosis and the influence of selenium Roland Gaertner (Munich, Germany)

The action of thyroid hormone analogues on angiogenesis Paul J. Davis (Albany, USA)

Olympic Hall II

- 12:30-12:45 Lunch Break
- 12:45-14:00 **Poster Discussion P120 to P191**

Poster Discussion 11 Genetics of thyroid disease Chairperson: Clara Alvarez (Santiago de Compostela, Spain) P120 EVIDENCE OF GENETIC ANTICIPATION IN FAMILIAL NON-MEDULLARY THYROID CANCER (FNMTC) Capezzone M.¹, Marchisotta S.¹, <u>Brilli L.¹</u>, Cantara S.¹, Busonero G.¹, Pazaitou-Panayiotou K.², Pacini F.¹ ¹Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Siena, Italy, ²Department of Endocrinology-Endocrine Oncology, Thessaloniki, Greece

P121 FETAL MICROCHIMERISM IN WOMEN WITH THYROID CANCER

<u>Cirello V.</u>¹, Perrino M.¹, Muzza M.¹, Colombo C.¹, Vicentini L.², Beck-Peccoz P.¹, Fugazzola L.¹ ¹Department of medical Sciences, Endocrine Unit, University of Milan, Fondazione Policlinico IRCCS, Milan, Italy, ²Endocrine Surgery Unit, Fondazione Policlinico IRCCS, Milan, Italy

P122 SCREENING OF RET PROTO-ONCOGENE POLYMORPHISMS IN PATIENTS WITH MEDULLARY THYROID CARCINOMA

<u>Vaclavikova E.</u>¹, Dvorakova S.¹, Sykorova V.¹, Strakova V.¹, Vlcek P.², Bendlova B.¹ ¹Dept. of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic, ²Dept. of Nuclear Medicine and Endocrinology of the 2nd Faculty of Medicine, Charles University and Hospital Motol, Prague, Czech Republic

P123 ANALYSIS OF THE RET G691S SINGLE NUCLEOTIDE POLYMORPHISM (SNP) IN PAPILLARY THYROID CARCINOMA

Cosci B., Romei C., Vivaldi A., Ciampi R., Molinaro E., Agate L., Bottici V., Renzini G., Pinchera A., Elisei R. Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy

P124 THE INHERITANCE OF CYP1B1 VARIANTS INCREASES THE RISK FOR GRAVES DISEASE IN THE BRAZILIAN POPULATION BUT DOES NOT INFLUENCE PATIENTS OUTCOME

Bufalo N.¹, Athie M.C.P.¹, Santos R.B.², Romaldini J.H.², <u>Ward L.S.¹</u> ¹Laboratory of Cancer Molecular Genetics, FCM, UNICAMP, Campinas, Sao Paulo, Brazil, ²Endocrinology, PUC-Campinas, Campinas, Sao Paulo, Brazil

P125 BCL1 POLYMORPHISM OF THE GLUCOCORTICOID RECEPTOR GENE IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE

Terzidis K.¹, Saltiki K.¹, Mantzou E.², Papageorgiou Ch.³, Zapanti E.¹, Anastasiou E.¹, Chroussos G.², Alevizaki M.²

¹Endocrine Unit, Dept Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, ²Endocrine Unit, Evgenidion Hospital, Athens University School of Medicine, ³Department of Psychiatry, Eginition Hospital, Athens University School of Medicine

P126 APOLIPOPROTEIN E AND PARAOXONASE 1 POLYMORPHISMS ARE ASSOCIATED WITH THYROID HYPOFUNCTION AND AUTOIMMUNITY IN POSTMENOPAUSAL WOMEN

Galapi F.¹, Lambrinoudaki I.¹, Kaparos G.², Rizos D.², Alexandrou A.³, Sergentanis Th.¹, Creatsa M.¹, Christodoulakos G.¹, Kouskouni E.², Botsis D.¹

¹2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, ² Hormonal and biochemical Laboratory, University of Athens, Aretaieio Hospital, Athens, Greece, ³ 1st Department of Surgery, University of Athens Medical School, Laiko Hospital, Athens, Greece

P127 INTERLEUKIN 1-BETA GENE (IL-1BETA) POLYMORPHISMS (SNP-511 AND SNP+3953) IN THYROID-ASSOCIATED OPTHALMOPATHY (TAO) AMONG THE POLISH POPULATION

Lacka K.¹, Paradowska A.², Gasinska T.³, Soszynska J.⁴, Wichary J.³, Kramer L.⁵, Lacki J. K.⁶

¹Department of Endocrinology, University of Medical Sciences, Poznan, Poland, ²Department of Biochemistry, Institute of Rheumatology, Warsaw, Poland, ³Department of Internal Medicine and Oncology, Silesian Medical University, Katowice, Poland, ⁴Unit of Internal Medicine, Poznan, Poland, ⁵Department of Computer Science and Statistics, University of Medical Sciences, Poznan, Poland, ⁶Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland 21



P128 NO ASSOCIATION BETWEEN ESTROGEN RECEPTOR ALPHA POLYMORPHISMS AND HASHIMOTOS THYROIDITIS

Boutina M.¹, Xita N.¹, Galidi A.², Dasoula A.², Georgiou I.², Vainas I.³, **Tsatsoulis A.¹** ¹Department of Endocrinology, University of Ioannina, Ioannina, Greece, ²Laboratory of Human Reproductive Genetics of University of Ioannina, Ioannina, Greece, ³Department of Endocrinology, Theagenion Hospital, Thessaloniki, Greece

P129 TOXIC MULTINODULAR GOITRE (TMNG) AND THE THYROID VOLUME ARE ASSOCIATED WITH CIGARETTE SMOKING BUT NOT THE TSHR GERMLINE POLYMORPHISM D727E

Jörn J., Miehle K., Schmidt C., Wicht J., **Paschke R.** III Medical Department, University of Leipzig, Germany

P130 PRIMARY THYROID CARCINOMA ASSOCIATED WITH OTHER MULTIPLE PRIMARY CANCERS. THE THEAGENION CANCER HOSPITAL EXPERIENCE

Pazaitou-Panayiotou K.¹, Papakotoulas P.¹, Georgiou E.¹, Boudina M.¹, Kiziridou A.², Vainas I.¹ ¹Department of Endocrinology-Endocrine Oncology, ²Department of Endocrinology-Endocrine and Pathology Theagenion Cancer Hospital, Thessaloniki, Greece

Poster Discussion 12

Thyroid cancer 3

Chairperson: Chantal Daumerie (Brussels, Belgium)

P131 CAMP INHIBITS THE PROLIFERATION OF THYROID CARCINOMA CELL LINES THROUGH REGULATION OF CDK4 PHOSPHORYLATION

Rocha A. S.¹, Paternot S.², Coulonval K.³, Soares P.⁴, Roger P.⁵ ¹IRIBHM Brussels, Belgium, IPATIMUP, Porto, Portugal, ²IRIBHM, Brussels, Belgium, ³IPATIMUP Porto, Portugal, ⁴IPATIMUP Porto, Portugal, ⁵IPATIMUP Porto, Portugal, ⁶IRIBHM, Brussels, Belgium

P132 CALCIUM/CALMODULIN-DEPENDENT KINASE II (CaMKII) IS CONSTITUTIVELY ACTIVATED IN THYROID CARCINOMAS

<u>Vitale M.</u>¹, Monaco S.², Rusciano M. R.², Salzano M.², Moretti M.I.¹, Fenzi G.¹, Rossi G.², Illario M.² ¹Department of Endocrinologia e Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Naples, Italy, ²Department of Biologia e patologia cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy

P133 HYDROGEN PEROXIDE IS A POTENTIAL MUTAGEN IN THYROID BY PROVOKING DNA SINGLE- AND DOUBLE-STRAND BREAKS

Driessens N., Ghaddhab Ch., Burniat A., De Deken X., Van Sande J., Dumont J. E., Miot F., Corvilain B. IRIBHM, Brussels, Belgium

P134 PERCUTANEOUS LASER ABLATION OF UNRESECTABLE BONE METASTASES FROM POORLY DIFFERENTIATED THYROID CARCINOMA

Papini E.¹, Bizzarri G.³, Baroli A.², Bianchini A.³, Anelli V.³, Guglielmi R.¹, Graziano F.¹, Pacella C. M.³ ¹Endocrinology and Metabolism, Ospedale Regina Apostolorum, Albano Laziale, Italy, ²Nuclear Medicine, Ospedale di Circolo, Busto Arsizio, Italy, ³Diagnastia Imaging, Ospedala Regina Apostolorum, Albano Laziale, Italy,

³Diagnostic Imaging, Ospedale Regina Apostolorum, Albano Laziale, Italy

P135 IMMUNOHISTOCHEMISTRY EXPRESSION OF p53 MAY HELP IDENTIFY THE PROGNOSTIC OF PAPILLARY THYROID CANCER PATIENTS

Morari E.C.¹, Silva J.R.¹, Guilhen A.C.T.¹, Araujo P.², Tincani A.J.², Assumpcao L. V.M.³, Vassallo J.⁴, Soares, F.⁵, Ward L.S.¹

¹Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School - FCM, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ²Division of Head and Neck, Department of Surgery, Medical Science School - FCM, State University of Campinas - UNICAMP,

State of Sao Paulo, Brazil, ³Division of Endocrinology, Department of Medicine, Medical Science School FCM, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ⁴Department of Pathology, Medical Science School - FCM, State University of Campinas -UNICAMP, State of Sao Paulo, Brazil, ⁵Department of Pathology, Hospital A.C.Camargo - Fundacao Antonio Prudente, Sao Paulo, Brazil

P136 IN-VITRO STUDIES ON TRANSKETOLASE LIKE 1 AS TARGET FOR THE TREATMENT OF THYROID CARCINOMAS

Froehlich E.¹, Fink I.¹, Czarnocka B.², Wahl R.¹

¹Internal Medicine, Dept. of Endocrinology, Metabolism, Nephrology and Clinical Chemistry, University of Tuebingen, Tuebingen, Germany, ²Medical Center of Postgraduate Education, Dept. of Biochemistry and Molecular Biology, University of Warsaw, Warsaw, Poland

P137 RADIATION-INDUCED THYROID STUNNING - DIFFERENTIAL EFFECTS OF I-123, I-131, TC-99M AND AT-211 ON IODIDE TRANSPORT AND NIS MRNA EXPRESSION IN CULTURED THYROID CELLS

Lundh C.¹, Lindencrona U.¹, Postgard P.¹, Carlsson T.², Nilsson M.², Forssell-Aronsson E.¹ ¹Radiation Physics, University of Gothenburg, Goteborg, Sweden, ²Medical Biochemistry and Cell Biology, University of Gothenburg, Goteborg, Sweden

P138 GENRISK-T PROJECT (*): SIGNAL TRANSDUCTION PATHWAYS IN RADIATION-INDUCED THYROID CANCER IN THE MOUSE

Derradji H., Abou-el-Ardat K., Leysen L., Michaux A., Baatout S. Laboratory of Molecular and Cellular Biology, Belgian Nuclear Research Center SCK-CEN Mol, Belgium

P139 GENRISK-T PROJECT: RESPONSE OF TPC-1 PAPILLARY THYROID CARCINOMA CELL LINE TO A RANGE OF LOW TO HIGH DOSES OF IRRADIATION
 <u>Abou-el-Ardat K.</u>^{1,2}, Derradji H.¹, Bekaert S.², De Meyer T.², Van Criekinge W.², Baatout S.¹
 ¹Laboratory of Molecular and Cellular Biology, Belgian Nuclear Research Center SCK-CEN Mol, Belgium, ²Department for Molecular Biotechnology, FBW, Ghent University Ghent, Belgium

P140 CAN THE RESULTS OF THE SECOND RECOMBINANT HUMAN THYROTROPIN STIMULATED THYROGLOBULIN TEST BE PREDICTED?

Biagini A., Passannanti P., Molinaro E., Viola D., Taddei D., Grasso L., Pinchera A., <u>Elisei R.</u> Department of Endocrinology and Metabolism, University of Pisa, Italy

P141 ECONOMIC EVALUATION OF USING RECOMBINANT HUMAN TSH PRIOR TO RADIOIODINE ABLATION FOR THYROID CANCER IN PORTUGAL

Pereira J.¹, Weston A.², Mernagh P.², Silva R.¹, Barbosa P.³, Rodrigues E.⁴, Carrilho F.⁵, Rodrigues F.⁶, Cruz-Ferreira T.⁷, Limbert E.⁷

¹Escola Nacional de Saude Publica, Universidade Nova de Lisboa, Lisboa, Portugal, ²Health Technology Analysts Pty Ltd, Sydney, Australia, ³Instituto Portugues de Oncologia do Porto, Porto, Portugal, ⁴Hospital de S. Joao, Porto, Portugal, ⁵Hospitais da Universidade de Coimbra, Coimbra, Portugal, ⁶Instituto Portugues de Oncologia de Coimbra, Coimbra, Portugal, ⁷Instituto Portugues de Oncologia de Lisboa de Francisco Gentil, Lisboa, Portugal

P142 DIAGNOSTIC ACCURACY OF ULTRASOUND AND 18F-FDG PET OR PET/CT IN PATIENTS WITH SUSPECTED RECURRENT PAPILLARY THYROID CARCINO

Huh M.O., Choi J.W., Choi B.S., Kim S.M., In H.S., <u>Lee J.H.</u> Department of Radiology, University of Ulsan Medical College, Asan Medical Center, Korea

P143 A USEFULNESS OF HIGHLY SENSITIVE THYROGLOBULIN (TG) ASSAY IN DIFFERENTIATED THYROID CARCINOMA PATIENTS UNDER THE TSH SUPPRESSION

Jang H.W., Lee J.I., Shin H.W., Oh E.Y., Kim S.W., Min Y.K., Lee M.S., Lee M.K., Kim K.W., Chung J.H. Department of Medicine, Samsung Medical center School of Medicine Sungkyunkwan University, Seoul, Korea

41

3



P144 CLINICAL COURSE AFTER RE-OPERATION FOR RECURRENT PAPILLARY THYROID CARCINOMA IN THE PATIENTS WITH HIGH STIMULATED THYROGLOBULIN VALUE AFTER TOTAL THYROIDECTOMY WITH REMNANT ABLATION

Jeong J. Y.¹, Kim W. G.¹, Kim T. Y.¹, Kim E. Y.¹, Gong G.², Hong S. J.³, Kim J. M.⁴, Kim W. B.¹, Shong Y. K.¹ ¹Department of Internal Medicine, Asan Medical Center/University of Ulsan College of Medicine, Seoul, Korea, ²Department of Pathology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea, ³Department of Surgery, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea, ⁴Thyroid Cancer Clinic, National Cancer Center Goyang, Korea

P145 INTERFERING THYROGLOBULIN ANTIBODIES (TGAB) ARE NOT ALWAYS DETECTED BY AUTOMATED TGAB ASSAYS IN PATIENTS WITH DIFFERENTIATED THYROID CANCERS (DTC)

Petrovic I.¹, Fatemi S.², Wei L.¹, Kazarosyan M.¹, Spencer C.¹ ¹University of Southern California, Los Angeles, CA, USA.²Kaiser Permanente, Panorama City, California, USA

P146 THE DIFFERENCES IN THE BALANCE BETWEEN APOPTOSIS AND PROLIFERATION IN PAPILLARY AND ANAPLASTIC THYROID CARCINOMA

Selemetjev S.¹, Cvejic D.¹, Savin S.¹, Paunovic I.², Tatic S.³

¹Institute for the Application of Nuclear Energy-INEP, Zemun-Belgrade, Serbia, ²Center for Endocrine Surgery, Clinical Center of Serbia, Belgrade, Serbia, ³Institute of Pathology, Medical Faculty, University of Belgrade, Serbia

Poster Discussion 13

Chairperson: Alexandra Chrisoulidou (Thessaloniki, Greece)

P147 DIFFERENTIATED THYROID CARCINOMAIN PEDIATRIC PATIENTS: SINGLE INSTITUTIONAL EXPERIENCE IN JAPAN

<u>Wada N.</u>¹, Sugino K.², Mimura T.², Nagahama M.², Kitagawa W.², Nakayama H.², Rino Y.¹, Masuda M.¹, Imada T.¹, Ito K.²

¹Department of Surgery, Yokohama City University, Yokohama, Kanagawa, Japan, ²Ito Hospital, Tokyo, Japan

P148 PROGNOSTIC FACTORS AND ITS IMPLICATION IN THE MANAGEMENT OF MICROPAPILLARY THYROID CARCINOMA

Araujo P.PC.¹, Tincani A.J.², Ward L.S.¹, Barreto G.³

¹Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ²Head and Neck Division, Department of Surgery, Medical Science School of University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ³Head and Neck Division, Medical Center of Campinas, State of Sao Paulo, Brazil

P149 MULTIFOCALITY AND ITS IMPLICATION IN THE MANAGEMENT OF PAPILLARY THYROID MICROCARCINOMAS

Araujo P.P.C.¹ Tincani A.J.1 Barreto G.² Ward L. S.¹

¹Molecular Genetics of Cancer Laboratory, Department of Internal Medicine, Medical Science School - FCM, State University of Campinas - UNICAMP, State of Sao Paulo, Brazil, ²Head and neck Service, Campinas Medical Center, State of Sao Paulo, Brazil

P150 CERVICAL MASSES PRESENTING SYMPTOMS OF PAPILLARY THYROID MICROCARCINOMAS

Pazaitou-Panayiotou K., **Boudina M.**, Drimonitis A., MaladakiA., Vainas I. Department of Endocrinology-Endocrine Oncology, ²Department of Pathology, Theagenion Cancer Hospital, Thessaloniki, Greece

Thyroid cancer 4



P151 TRENDS IN THE INCIDENCE OF FOLLICULAR (FTC) AND PAPILLARY (PTC) CARCINOMA IN GREECE: RESULTS IN ONE CENTRE, 1963-2007

Papageorgiou G.¹, Retziou I.¹ Saltiki K.¹, Marafelia P.², Loukari E.², Koutras D.², Alevizaki M.¹ ¹Endocrine Unit, Dept Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, ²Endocrine Unit, Evgenidion Hospital, Athens University School of Medicine

P152 SHORT-TERM CLINICAL RESULTS IN OUR ALTERED TREATMENT STRATEGY (TOTAL THYROIDECTOMY WITH BILATERAL MODIFIED NECK DISSECTION AND RADIOACTIVE IODINE THERAPY) FOR PAPILLARY THYROID CARCINOMA PRESENTING WITH GROSS LATERAL NODE METASTASIS

Nakayama H.¹, Sugino K., Yano Y.¹, Ohkuwa K.¹, Sibuya H.¹, Kitagawa W.¹, Nagahama M.¹, Ito K.¹, Ito K.¹, Wada N.²

¹Surgery, Ito Hospital, Tokyo, Japan, ²Surgery, Yokohama City University Hospital, Yokohama, Japan

P153 WHICH THYROID CARCINOMA WITH CAPSULAR INVASION IS CORRELATED WITH LYMPH NODE METASTASIS?

Jung S.¹, Kim B.¹, Choi N.¹, Kim J.², Ahn K.²

¹Radiology, Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, ²Radiology, St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

P154 CLINICO-PATHOLOGICAL FEATURES OF SCREEN DETECTED THYROID CANCER COMPARE TO OVERT CLINICAL THYROID CANCER

<u>Choi Y.</u>, Kim B.

Department of Radiology Kangbuk Samsung Hospital, Sungkyunkwan University Seoul, Korea

P155 OPTIMISING THE DOSE OF LEVOTHYROXINE EARLY AFTER RADIOACTIVE IODINE ABLATION IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

Conduit B.¹, Sinclair J.², Mallick U. K.², Ravikumar B.¹, Perros P.¹ ¹Department of Endocrinology, Freeman Hospital, Newcastle Upon Tyne, UK, ²Department of Clinical Oncology, Northern Centre for Cancer Treatment (NCCT), Freeman Hospital, Newcastle upon Tyne, UK

P156 LEVOTHYROXINE DOSAGE REQUIRED FOR TSH-SUPPRESSION IN DIFFERENTIATED THYROID CARCINOMA PATIENTS DECREASES OVER TIME

Verburg F.¹, Mäder U.², Luster M.¹ Reiners C.¹, Smit J.³

¹Department of Nuclear Medicine, University Clinic Würzburg, Würzburg, Germany, ²Tumour Centre, University Clinic Würzburg, Würzburg, Germany, ³Department of Endocrinology, University Hospital Leiden, Leiden, The Netherlands

P157 LEVOTHYROXINE SUBSTITUTION IN PATIENTS AFTER SURGERY AND RADIOIODINE THERAPY FOR RADIATION INDUCED THYROID CARCINOMA AFTER CHERNOBYL

Drozd V.M.¹, Leonova T.A.², Mityukova T.A.², Lushchyk M.L.², Platonova T.Y.², Biko I.³, Reiners Ch.³ ¹Belarusian-German Fund "Arnica", Minsk, Belarus, ²Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus, ³Clinic and Policlinic of Nuclear Medicine, University of Würzburg, Würzburg, Germany

P158 CLINICAL SIGNIFICANCE OF SERUM THYROGLOBULIN LEVELS IN PATIENTS WITH WELL DIFFERENTIATED THYROID CARCINOMA AFTER TOTAL THYROIDECTOMY Jung T.S., Kim S.K., Chung S.I., Hahm J.R.

Department of Internal Medicine, Gyeongsang National University School of Medicine

P159 MEDULLARY THYROID CARCINOMA CLINICAL COURSE AND THE ROLE OF GENETIC EXAMINATION <u>Przybylik-Mazurek E.</u>¹, Hubalewska-Dydejczyk A.¹, Gubala E.², Pawlaczek A.², Oczko - Wojciechowska M.², Wygoda Z.², Szybiski Z.¹, Jarzab B.²

¹Chair and Department of Endocrinology Collegium Medicum Jagiellonian University in Kraków, ²Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch 20



P160 COEXISTENCE OF PAPILLARY AND MEDULLARY THYROID CARCINOMA: A CASE REPORT

Bayrak E., Serter R., Donderici O. Internal Medicine Ankara Education and Research Hospital Ankara Turkey

P161 RECOMBINANT HUMAN THYROTROPIN IN CLINICAL PRACTICE

<u>Alves M.</u>, Neves C., Queirós J., Rodrigues E., Carvalho D., Medina J. L. Service of Endocrinology, Hospital Day of Endocrinology, S. João Hospital, EPE, Faculty of Medicine, University of Porto, Porto, Portugal

P162 ASSAY-DEPENDENT INTERFERENCE OF NORMAL THYROGLOBULIN-ANTIBODY LEVELS WITH THYROGLOBULIN MEASUREMENT

Szabolcs I.¹, Toldy E.², Locsey Z.³, Kovacs L.G.⁴

¹Department of Endocrinology, State Health Center and Semmelweis University Budapest, Hungary, ²Central Laboratory, Markusovszky Teaching Hospital of County Vas, Szombathely and Department of Practical Diagnostics, University of Pecs, Hungary, ³Department of Medicine, Markusovszky Teaching Hospital of County Vas, Szombathely, Hungary, ⁴Institute of Laboratory Medicine, University of Pecs, Hungary

Poster Discussion 14

Clinical thyroidology 4. Nodules & goitre

Chairperson: Joao Jacome Castro (Lisbon, Portugal)

P163 HASHIMOTOS THYROIDITIS AS WELL AS HIGHER SERUM TSH LEVELS IS ASSOCIATED WITH A RISK OF DIFFERENTIATED THYROID CANCER IN KOREAN PATIENTS WITH THYROID NODULE

Kim K.W.¹, Kim E.H.², Lee H.E.³, Park S.Y.³, Park Y.J.¹, Park D.J.¹, Jang H.C.¹, Cho B.Y.¹ ¹Department of Internal Medicine Seoull National University College of Medicine, Seoul, Korea, ²Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Korea, ³Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

P164 HASHIMOTO'S THYROIDITIS (HT) AND THYROID CANCER: FURTHER SEROLOGICAL CYTOLOGICAL AND HISTOLOGICAL STUDIES

Boi F.¹, Spanu F.¹, Figus B.¹, Marziani B.¹, Matta V.¹, Baghino G.¹, Lai M.L², Mariotti S.¹ ¹Endocrinology, Department of Medical Sciences "M. Aresu", ²Department of Cytomorphology, University of Cagliari

P165 MICROCYSTIC APPEARANCE, BENIGN SONOGRAPHIC FEATURE OF THYROID NODULE?

<u>**Kim J.Y.**</u>¹, Jung S.L.², Ahn K.J.¹, Kim B.S.² ¹Department of Radiology, St. Mary's Hospital, Seoul, Korea, ²Department of Radiology, Kangnam St. Mary's Hospital, Seoul, Korea

P166 ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION BIOPSY FOR THYROID NODULES: EMPHASIS ON TECHNIQUE

<u>Kim D. W.</u>, Lee E. J. Department of Radiology, Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea

P167 ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION BIOPSY OF THYROID NODULES: COMPARISON IN EFFICACY ACCORDING TO NODULE SIZE

Kim D.W.¹, Lee E.J.¹, Kim S.H.², Kim T.H.², Lee S.H.², Kim D.H.³, Rho M.H.⁴

¹Department of Radiology, Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea, ²Department of General Surgery (Thyroid & Breast Clinic), Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea, ³Department of Occupational and Environmental Medicine, Busan Paik Hospital, Inje University School of Medicine, Busan, South Korea, ⁴Department of Radiology, Masan Samsung Hospital, Sungkyunkwan University School of Medicine, South Korea



P168 REPEATED FINE-NEEDLE ASPIRATION OF THE THYROID NODULES WITH BENIGN CYTOLOGIC RESULTS. IS IT REALLY USEFUL?

Fotou M., Drouveli Th., Oikonomou V., <u>Koniaris E.</u>, Kotzia E. Department of Clinical Cytology, "Hippokratio" General Hospital of Athens

P169 THE ADDED VALUE OF US-GUIDED CORE NEEDLE BIOPSY OVER THAT OF FINE NEEDLE ASPIRATION FOR THE DIAGNOSIS OF THYROID MALIGNANCY

Na D. G.¹, Baek J. H.², Kim Y. S.²

¹Department of Radiology, Thyroid clinic center, Human Medical Imaging & Intervention Center, Seoul, Korea, ²Department of Radiology, Thyroid center, Daerim St. Marys Hospital, Seoul, Korea

- P170 ANALYSIS OF NONDIAGNOSTIC THYROID FINE-NEEDLE ASPIRATIONS (FNA) Fotou M., Oikonomou V., Drouveli Th., <u>Koniaris E.</u>, Kotzia E. Department of Clinical Cytology "Hippokratio"General Hospital of Athens
- P171 RADIOFREQUENCY ABLATION (RFA) IN THE TREATMENT OF AUTONOMOUSLY FUNCTIONING THYROID NODULES (AFTN)

Baek J.H.¹ Kim Y.S.¹ Kwak M.S.¹ Moon W.J.² ¹Department of radiology, Thyroid center, Daerim St. Marys Hospital, Seoul, Korea, ²Department of Radiology, Konkuk University Hospital, Konkuk University School of Medicine, Seoul, Korea

P172 THE EFFECTS OF URAEMIA IN THE PROGRESS OF THYROID NODULAR GOITER Katsarou I.

Renal Unit of General Hospital of Zakynthos, Greece

P173 HYPERCALCITONINEMIA WITHOUT CYTOLOGICAL EVIDENCE OF MEDULLARY THYROID CANCER IN PATIENTS WITH NODULAR THYROID DISEASE WARRANTS INTENSIVE INVESTIGATION TO RULE-OUT SPURIOUS HYPERCALCITONINEMIA CAUSED BY HETEROPHILIC ANTIBODIES Lee J.I.¹, Kim J.M.², Kim J.N.² Won W.J², Won J.H.¹, Won S.H.¹, Kim S.W.¹, Chung J.H.¹ ¹Department of endocrinology and metabolism, Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul, Korea, ²Research institute and hospital National Cancer Center, Seoul, Korea

P174 PECULIARITIES OF TREATING PATIENTS AFTER THYROID SURGERY <u>Gasparyan E.</u>, Goroshko O., Chursina E. Medical Academy of Postgraduate Studies, "Professor" Medical Centre, St. Petersburg, Russia

P175 THYROID TUBERCULOSIS: DIFFERENTIAL DIAGNOSIS OF ANTERIOR CERVICAL MASS. CASE REPORT Pavin E.J., Silva B.P., Amorim E.G., Ferrari M.T.M., Matos P.S., <u>Zantut-Wittmann D.E.</u> Endocrinology Division, Departments of Internal Medicine and Anatomical Pathology, School of Medical

Endocrinology Division, Departments of Internal Medicine and Anatomical Pathology, School of Medical Sciences, State University of Campinas, Campinas, Sao Paulo, Brazil

P176 SUPERIOR VENA CAVA SYNDROME AND INTRATHORACIC GOITER <u>Marcelino M.</u>, Nobre E., Conceicao J., Guerra S., Vilar H., De Castro J. J. Servico de Endocrinologia, Diabetes e Metabolismo, Hospital Militar Principal, Lisboa, Portugal

Poster Discussion 15 Clinical thyroidology 3 FNA & cancer Chairperson: Valentin Fadeyev (Moscow, Russia)

P177 DIFFICULTTIES IN THE ABSORPTION OF LEVOTHYROXINE: IMPROVEMENT USING VITAMIN C Licht S.¹, Antunez P.²

¹Private Practice, ²University of Buenos Aires



P178 SILENT CELIAC DISEASE AS OCCULT CAUSE OF THYROXINE MALABSORPTION IN PATIENTS WITH CHRONIC LYMPHOCITIC THYROIDITIS

Gargano L., Santaguida M. G., Virili C., Del Duca S. C.¹, <u>Centanni M.</u>¹ University «Sapienza» of Rome, Polo Pontino, Latina, Italy

P179 L-THYROXIN REPLACEMENT THERAPY: FACTORS OF COMPENSATION QUALITY

Fadeyev V., Morgunova T., Manuylova Y. Department of Endocrinology, Moscow Medical Academy, Moscow, Russia

P180 HYPONATREMIA ASSOCIATED WITH INADEQUATELY TREATED PRIMARY HYPOTHYROIDISM. A HOSPITAL-BASED, RETROSPECTIVE STUDY

Rammos G., Panoutsopoulos A. Peppes V., Koufogiorga E., Kostopoulos K., Tourli P. Department of Clinical Therapeutics, University of Athens Medical School, Alexandra Hospital, Athens, Greece

P181 THE NORMAL DISTRIBUTION OF TSH IS INFLUENCED BY AGE

De Remigis P.¹, Lattanzio M.F.², De Laurentis B.², De Remigis A.¹, Matera S.², Vianale L.¹ ¹Endocrine Unit, ²Clinic Pathology, Chiety, Italy

P182 INFLUENCE OF TESTING INTERVAL AND T4 ESTIMATION METHOD ON MONITORING OF SUBCLINICAL HYPOTHYROIDISM

Karmisholt J., Andersen S., Laurberg P. Dept. of Medical Endocrinology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark

P183 THYROID FUNCTION AND VOLUME CHANGES IN PATIENTS WITH END STAGE RENAL DISEASE, BEFORE AND AFTER KIDNEY TRANSPLANTATION

Sarvghadi F.¹, Tara A.²

¹Endocrine Research Institute, Taleghani General Hospital, Tehran, I. R. Iran, ²Nephrology ward, Shaheed Modarres General Hospital, Tehran, I. R. Iran

P184 THYROID DISORDERS IN PATIENTS WITH TURNER SYNDROME Moradi S.

Endocrinology and metabolism, Institute of endocrine and metabolism, Firouzgar, Tehran, Iran

P185 A PATIENT WITH GRAVE'S DISEASE IN WHOM THE RUPTURE OF A RENAL ANEURYSM DURING PREGNANCY INDUCED THYROTOXIC CRISIS

<u>Nakata Y.</u>¹, Ogita K.², Yamamoto R.², Miyake A.², Tamaki Y.³, Okabe T.³, Osuga K.⁴, Higashihara H., Kouno M.⁵, Sugimoto H.⁵, Kimura T.², Shimomura I.⁶

¹Dept. of Laboratory Medicine, Osaka University Medical School, Suita, Osaka, Japan, ²Dept. of Obstetrics and Gynecology, Osaka University Medical School, Suita, Osaka, Japan, ³Dept. of Breast and Endocrine Surgery, Osaka University Medical School, Suita, Osaka, Japan, ⁴Dept. of Diagnostic and Interventional Radiology, Osaka University Medical School, Suita, Osaka, Japan, ⁵Dept. of Traumatology and Acute Critical Medicine, Osaka University Medical School, Suita, Osaka, Japan, ⁶Dept. of Metabolic Medicine, Osaka University Medical School, Suita, Osaka, Japan, ⁶Dept. of Metabolic Medicine,

P186 THYROID STORM AFTER THE LIVER TRANSPLANTATION IN A PATIENT WITH HEPATIC CIRRHOSIS

Spassov L.¹, **Lozanov B.**¹, Pashev V.¹, Sechanov T.² ¹University Hospital "Lozenets", Sofia, Bulgaria, ²Clinical Center of Endocrinology, Sofia, Bulgaria

P187 THYROID STORM INDUCED BY BLUNT THYROID GLAND TRAUMA

Christodoulidis G.¹, Delikoukos S.², Anagnostoulis S.², Hatzitheofilou K.¹ ¹Gen. Surg. Dep., University Hospital Of Larissa, Larissa, Greece, ²Gen. Surg. Dep. Euromedica Blue Cross Clinic, Larissa, Greece



 P188 THYROTOXIC HYPOKALEMIC PERIODIC PARALYSIS (THPP): CLINICAL COURSES IN THREE MEN FOLLOWED IN ONE EUROPEAN INSTITUTION Diarra D., Waldhaeusl W., <u>Weissel M.</u> Clinic for Internal Medicine, Medical University of Vienna, Austria
 P189 COEXISTING HYPERTHYROIDISM AND THYROID CANCER: A 5-YEAR STUDY Manouras A., <u>Michalopoulos N.</u>, Markogiannakis H., Lagoudianakis E., Panoussopoulos S. G., Bramis

C., Filis K., Sigala F., Kekis P., Manouras A. Department of Endocrine Surgery, 1st Department of Propaedeutic Surgery, Hippokrateion Hospital, Athens, Greece

P190 COMPINATION THERAPY FOR PREDOMINANTLY CYSTIC THYROID NODULES (PCTNs): ETHANOL ABLATION (EA) FOLLOWED BY RADIOFREQUENCY ABLATION (RFA) <u>Kim Y. S</u>., Baek J. H., Jeong H. J., Kwak M. S.

Department of radiology, Thyroid center, Daerim St. Marys Hospital, Seoul, Korea

P191 PREDICTIVE VALUE OF LOW-TITER THYROID PEROXIDASE SEROPOSITIVITY FOR HYPOTHYROIDISM IN EUTHYROID HASHIMOTOS THYROIDIS: 3 YEARS FOLLOW-UP

Dagdelen S., Unluturk U., <u>**Erbas T.,**</u> Usman A. Hacettepe Medical School, Department of Endocrinology, Ankara, Turkey

Olympic Hall I

- 14:00-14:50 The European Thyroid Association/Merck KGaA Prize Familial non-medullary thyroid cancer: clinical and genetic features Furio Pacini (Siena, Italy)
- 15:00-15:45 Meet the Experts 7 New drugs and interference with thyroid function Mark Vanderpump (London, UK)

Olympic Hall III

15:00-15:45 **Meet the Experts 8 The HPT – axis setpoint: an update Peter Laurberg** (Aalborg, Denmark)

Meliton Hotel - Erato Hall

15:00-15:45 Meet the Experts 6 Thyroid hormone transporters Edith Friesema (Rotterdam, The Netherlands)

Meliton Hotel -Terpsichori Hall

15:00-15:45 **Meet the Experts 9 T/C supersensitive Tg assays Ulla Feldt – Rasmussen** (Copenhagen, Denmark)



15:45-16:00 Coffee Break



Olympic Hall I

2 22 Tuesday 23

16:00-17:15 Symposium 8

Selenium and thyroid disease Chairpersons: Charles Emerson (Florida, USA) Jad Mouslesh (Thessaloniki, Greece)

Introduction – Selenium status, selenoproteins and the thyroid hormone axis Lutz Schomburg (Berlin, Germany)

Mutations in SECIS binding protein 2 – illuminating a new disease resulting in abnormal thyroid hormone metabolism Krishna Chatterjee (Cambridge, UK)

Selenium and autoimmune thyroid disease: A new way in preventing of post partum thyroiditis? Roberto Negro (Lecce, Italy)

Olympic Hall III)

16:00-17:15 **Oral session 6**

Young Investigators

Chairpersons: Michael Weissel (Vienna, Austria) Kalliopi Pazaitou – Panayiotou (Thessaloniki, Greece)

047 SEVEREGRANULOMATOUS EXPERIMENTAL AUTOIMMUNE THYROIDITIS INDUCED BYIMMUNIZATION OF CBA/J (H-2k) MICE WITH HYDROPHOBIC INTERMEDIATES OF THYROGLOBULIN DISSOCIATION/ UNFOLDING IN UREA

Arcaro A.¹, **<u>D'Angelo D.</u>²**, Cetrangolo G.¹, Luise C.², Nucci R.³, Febbraio F.³, Fulciniti F.⁴, Formisano S.², Gentile F.¹

¹Dipartimento di Scienze per la Salute, Universita del Molise, Campobasso, Italy, ²Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita Federico II, Napoli, Italy, ³Istituto di Biochimica delle Proteine del Consiglio Nazionale delle Ricerche, Napoli, Italy, ⁴Istituto Nazionale dei Tumori "Fondazione Pascale", Napoli, Italy

048 A CASE-CONTROL STUDY OF CDKN1B (P27) POLYMORPHISMS IN THYROID CANCER IDENTIFIES A SIGNIFICANT SNP WITH AN EFFECT AT THE TRANSCRIPTIONAL LEVEL

Landa I.¹, Montero-Conde C.¹, Malanga D.^{2,3}, De Gisi S.³, Letón R.¹, De Marco C.^{2,3}, Viglietto G.^{2,3}, Robledo M.¹

¹Hereditary Endocrine Cancer Group, CNIO, Spain, ²University Magna Graecia Catanzaro, Italy, ³Institute for Genetic Research IRGS, Ariano irpino (AV), Italy

049 ROLE OF OATP1 SUBFAMILY IN IODOTHYRONINE (SULFATE) TRANSPORT AND METABOLISM <u>Van der Deure W.</u>, Peeters R., Visser T.

Department of Internal Medicine, Erasmus University Medical Center Rotterdam, The Netherlands

050 A FUNCTIONAL CROSS-TALK BETWEEN THYROID HORMONE AND SONIC HEDGEHOG PATHWAYS IN THE TUMORIGENESIS OF BASAL CELL CARCINOMA

Dentice M.¹, Luongo C.¹, Ambrosio R.¹, Aristarco V.¹, Casillo A.¹, D'Ambrosio R.¹, Mansi C.¹, Fenzi G.¹, Larsen PR.², Salvatore D.¹

¹Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università di Napoli "Federico II", Naples, Italy, ²Division of Endocrinology, Brigham and Womens Hospital, Harvard, Boston, USA



051 BRAFV600E MUTATION IS A BAD PROGNOSTIC FACTOR BOTH FOR THE OUTCOME AND SURVIVAL OF PAPILLARY THYROID CANCER PATIENTS

<u>Viola D.</u>¹, Ugolini C.², Lupi C.², Biagini A.¹, Giannini R.², Romei C.¹, Miccoli P.³, Pinchera A.¹, Basolo F.², Rossella E.¹

¹Department of Endocrinology, Azienda-Ospedaliero Universitaria Pisana, Pisa, Italy,

²Department of Oncology, Azienda-Ospedaliero Universitaria Pisana, Pisa, Italy,

³Department of Surgery, Azienda-Ospedaliero Universitaria Pisana, Pisa, Italy

052 THYROID FUNCTION STATUS, CARDIOVASCULAR RISK FACTORS AND MORTALITY IN OLDER PERSONS

Gopinath B.^{1, 2}, Wang J.J.^{1, 3}, Kifley A.¹, Leeder S.R.², Mitchell P.¹

¹Centre for Vision Research, Department of Ophthalmology, Westmead Millennium Institute, University of Sydney, NSW, Australia,²Australian Health Policy Institute, University of Sydney, Sydney, NSW, Australia,³Centre for Eye Research Australia, Department of Ophthalmology, University of Melbourne, Melbourne, Victoria, Australia

Olympic Hall I

17:15-18:30 General Assembly

Departure for the Gala Dinner (page 55)



Wednesday, September 24th, 2008

Olympic Hall I

08:30-10:30 **Topic Highlights 2**

Chairpersons: Ulla Feldt-Rasmussen (Copenhagen, Denmark) Peter Laurberg (Aalborg, Denmark)

053 MOLECULAR MIMICRY BETWEEN THYROID STIMULATING AUOANTIBODY AND TSH BINDING TO THE TSH RECEPTOR

Nunez Miguel R.^{1,2}, Chirgadze D.Y.², Sanders J.¹, Blundell T.L.², Furmaniak J.¹, Rees Smith B.¹ ¹FIRS Laboratories, RSR Ltd, Parc Ty Glas, Llanishen, Cardiff, UK, ²Department of Biochemistry, University of Cambridge, Cambridge, UK

054 HIGHER MATERNAL TSH LEVELS IN EARLY PREGNANCY ARE ASSOCIATED WITH INCREASED RISK FOR MISCARRIAGE, FETAL OR NEONATAL DEATH

Benhadi N.¹, Wiersinga W.M.¹, Reitsma J.², Vrijkotte T.³, Bonsel G.³

¹Department of Endocrinology and Metabolism, Academic medical Centre Amsterdam, The Netherlands, ²Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre Amsterdam, the Netherlands, ³Department of Social Science, Academic Medical Centre Amsterdam, The Netherlands

055 REACTIVATION OF THE P53 PATHWAY AND INDUCTION OF APOPTOSIS IN THYROID CARCINOMA CELLS BY THE CELL-PERMEABLE SYNTHETIC PEPTIDE P46, THE SMALL MOLECULE PRIMA-1 OR THE HDM2 INHIBITOR NUTLIN-3: THERAPEUTIC IMPLICATIONS

Hayden P.¹, Kotoula V.², McMillin W.D. ¹, Negri J.¹, Mitsiades S.C.¹, Mitsiades N.^{1,3}

¹Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston MA, USA, ²Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Greece, ³Memorial Sloan Kettering Cancer Center, New York, USA

056 A PHASE II STUDY OF SORAFENIB IN ADVANCED METASTATIC THYROID CARCINOMA

Brose S. M.¹, Nellore A.², Paziana K.³, Pappas-Paxinos M.³, Redlinger M.¹, Flaherty T.K.¹, Mandel J.S.², Troxel J.A.⁴, Loevner A.L.⁵, Gupta-Abramson V.²

¹Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA, ²Departmentof Medicine, University of Pennsylvania, Philadelphia, PA, USA, ³Department of Otorhinolaryngology, Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA, ⁴Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA, ⁵Department of Radiology, University of Pennsylvania, Philadelphia, USA

057 MODIFIED PROTEOME PATTERNS OF TEAR FLUID IN GRAVES ORBITOPATHY

Okrojek R., Grus F., Matheis N., <u>Kahaly G.J.</u>

Gutenberg University Hospital, Mainz, Germany

058 INCREASED SKELETAL MINERALISATION IN MICE LACKING TYPE 2 IODOTHYRONINE DEIODINASE

Bassett J.H. D.¹, Boyde A.², Howell G.T.P.³, Galliford M.T.¹, Archanco M.¹, Germain L.S. D.⁴, Galton A.V.⁴, Williams G.R.¹

¹Molecular Endocrinology Group, Imperial College London, London, UK, ²Centre for Oral Growth and Development, Queen Mary, University of London, London, UK, ³Eastman Dental Institute, University College London, London, UK, ⁴Department of Physiology, Dartmouth Medical School, Lebanon, New Hampshire, USA



Olympic Hall II

10:30-11:00 Coffee Break

Olympic Hall I

11:00-12:45 Symposium 9 (Clinical) Thyroid, pregnancy and fertility: From guidelines to practice Chairpersons: Brigitte Velkeniers (Brussels, Belgium) Avraam Avramidis (Thessaloniki, Greece)

The 2007 clinical guidelines for the management of thyroid disorders associated with pregnancy: a critical overview Daniel Glinoer (Brussels, Belgium)

Thyroid disorders and infertility Kris Poppe (Brussels, Belgium)

Thyroid autoimmune disorders and miscarriage Luca Chiovato (Pisa, Italy)

Olympic Hall III

- 11:00-12:45 Oral Session 7 Thyroid cancer 2 Chairpersons: Barbara Jarzab (Gliwice, Poland) Ioanna Tzavara (Athens, Greece)
- **059 MOLECULAR CHARACTERISTICS OF PAPILLARY THYROID CARCINOMAS WITHOUT BRAF MUTATION AND WITHOUT RET/PTC REARRANGEMENT: RELATIONSHIP WITH CLINICOPATHOLOGICAL FEATURES** Durand S.¹, Ferraro-Peyret C.¹, Selmi-Ruby S.¹, Borson-Chazot F.^{1,2}, **Rousset B.**^{1,2} ¹Inserm UMR 664, ²Thyroid Tumor Bank Organization, Hospices Civils de Lyon
- 060 SHORT TELOMERES, hTERT GENE AMPLIFICATION AND INCREASED TELOMERASE ACTIVITY IN THE BLOOD OF FAMILIAL NON-MEDULLARY THYROID CANCER PATIENTS

Cantara S.¹, Capezzone M.¹, Marchisotta S.¹, Busonero G.¹, Filetti S.², <u>Pacini F.¹</u> ¹Section of Endocrinology & Metabolism, Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, University of Siena, Siena, Italy, ²Department of Clinical Sciences, University of Rome, Rome, Italy

061 MIR-21 DEREGULATION IN THYROID CANCER

Frezzetti D.¹, Guerra C.², Barbacid M.², Di Lauro R.³, **De Vita G.**⁴ ¹Biogem s.c.a r.l. Ariano Irpino, ²CNIO, Madrid, ³Stazione Zoologica Anton Dohrn Napoli, 4Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università di Napoli

062 IMPLICATION OF MTOR IN CAMP-DEPENDENT MITOGENESIS IN THYROID CELLS

Blancquaert S.¹, Wang L.², Paternot S.¹, Harris Th.², Roger P.P.¹ ¹IRIBHM, ULB, Campus Erasme, Brussels, Belgium, ²University of Virginia, Department of Pharmacology, USA 2

22



063 TRANSIENT HYPOTHYROIDSM INDUCED BY SUNITINIB, AN ANTI-TUMORAL THYROSINE-KINASE SELECTIVE INHIBITOR, IS ASSOCIATED WITH OTHER ENDOCRINE DYSFUNCTIONS

Mannavola D.¹, Vannucchi G.¹, Covelli D.¹, Coco P.², Bertulli R.², Casali P.², Beck-Peccoz P.¹, Fugazzola L.¹ ¹Department of Medical Sciences, Endocrine Unit, University of Milan, IRCCS FondazionePoliclinico, MIlan , Italy, ²Department of Oncology, Istituto Nazionale dei Tumori, Milan, Italy

064 RAPAMYCIN TREATMENT IMPAIRS THE PROLIFERATION OF THYROID CARCINOMA CELL LINES IN AN ONCOGENE DEPENDENT MANNER

<u>Rocha A.S.</u>¹, Blancquaert S.², Pópulo H.³, Faustino A.⁴, Soares P.⁵, Roger P.⁶ ¹IRIBHM, IPATIMUP, ²IRIBHM, ³IPATIMUP, ⁴IPATIMUP, ⁵IPATIMUP, ⁶IRIBHM

065 MEASUREMENT OF BASAL SERUM THYROGLOBULIN (TG) WITH ULTRASENSITIVE ASSAYS ON LEVO-THYROXINE THERAPY (LT4) IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA (DTC): TOO EARLY TO DISMISS THE rhTSH STIMULATION TEST

<u>Castagna M. G.</u>, Cipri C., Tala H., Fioravanti C., Pasqui L., Sestini F., Brilli L., Belardini V., Ghezzi M., Pacini F.

Department of Internal Medicine, Endocrinology, Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Italy

066 PREDICTION OF THE LOW-RISK PAPILLARY THYROID CANCER BY A MULTIGENE CLASSIFIER

Szpak-Ulczok S.¹, Jarzab M.², Oczko-Wojciechowska M.¹, Kowalska M.¹, Kowal M.¹, Pfeifer A.¹, Czarniecka A.³, Roskosz J.¹, Handkiewicz-Junak D.¹, Jarzab B.¹

¹Department of Nuclear Medicine and Endocrine Oncology, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, ²Department of Clinical Oncology, Department of Tumor Biology, MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, ³Clinic of Oncological and Reconstructive Surgery, MSC Memorial Cancer Center and Institute of Oncology

Olympic Hall I

13:00-14:00 Closing Ceremony

Invitation to Lisbon



SOCIAL EVENTS

Saturday, September 20th, 2008

Welcome Reception

20:00-22:30 | Meliton Hotel – by the Pool

The welcome reception will take place by the pool of the Meliton Hotel. All congress participants and accompanying persons are invited and will have the opportunity to enjoy famous Greek specialities, fine "Porto Carras" wine and Greek music.

Transportation will be available at the end of welcome reception from Porto Carras to Marmaras village for participants who stay at Marmaras hotels.







Monday, September 22nd, 2008

Excursion and dinner

16:00-23:00 | Cruise with boat Menia Maria III

MENIA MAPIA is a galera-like boat, built in Thessaloniki in 2002, 50 metres length and total capacity of 620 persons.

Buses will depart from Porto Carras at 16.00 to Ormos Panagia port at Sithonia, 15-20 minutes drive, where embarkation will take place. Dinner, wine and great music on board all free of charge.

In case of bad weather, a bus-tour around the second "leg" of Chalkidiki peninsula will take place and dinner will be provided at Agios Mamas Municipal cultural center.

Return to Porto Carras and Marmaras village at 23.00.

All congress participants and accompanying persons are invited free of charge. However due to limited boat spaces an early registration is strongly required.





Tuesday, September 23nd, 2008

Gala dinner

21:00-23:30 | Tradiotional Greek Tavern

The Gala dinner of the 33rd Annual Meeting will take place at a lovely nearby fish tavern overlooking a private bay. Busses will depart from Porto Carras at 19.00.

Pre-paid tickets (50 euros) will be included in the congress envelope.

The ticket must be handed to the staff at the entrance.

Registered participants may purchase tickets from the registration desk depending on availability (on site = 55 euros).

Greek music and dancing until midnight.

Buses will be available for return to Porto Carras or Marmaras village at 22.30, 23.00 and 23.30.









REGISTRATION

MAIN CONFERENCE FEES	on-Site	On day registration
 ETA Ordinary / Senior Member 	260 €	100 €
• ETA Junior Member	210 €	100 €
ETA Corresponding Member	400 €	100 €
• Non - Member	460 €	150 €
Student / Research Fellow	310 €	100 €
Accompanying Person	120 €	
Pre-Conference Fees		
• ETA/CRN	100 €	
ICCIDD	40€	
Ultrasonography Course	150 €	
Social Program		
• Gala Dinner	55 €	

Registration Package

The registration fee includes:

Participants:

- Attendance to the scientific sessions and entry to exhibition hall
- Congress Material
- Attendance to the Opening Ceremony and Welcome Reception
- Coffee breaks and light lunches
- Congress Material
- Certificate of attendance
- Excursion

Accompanying Persons:

- Attendance to the Opening Ceremony and Welcome Reception
- Excursion

ETA/CRN

• Admission to the Scientific Sessions of ETA/CRN, congress material, lunch and coffee breaks

ICCIDD

• Admission to the Scientific Sessions of ICCIDD, congress material, lunch and coffee breaks

Practical Diagnostic Thyroid and Parathyroid Ultrasonography Course

• Admission to the Scientific Sessions of Course, congress material, lunch and coffee breaks

On site Registration / Secretariat Desk

The Conference secretariat will be located in the lobby of the Olympic Hall. The Secretariat will operate during the following hours:

No registration, access for exhibitors only
07.00-19.00
06.00-18.00
06.00-16.00
06.00-18.00
08.00-14.00



GENERAL INFORMATION

Oral Presentation

Powerpoint is the preferred format for presentation. Presenters must submit their presentations at least 1 hour prior to their session. All conference rooms are fully equipped with a pc/notebook for presentation, data video projector and screen. It will not be possible to use slides. Please note that there will be no facilities for overhead projection.

Personal notebooks will not be permitted.

Poster Displays

Poster boards are 80 cm width by 120 cm height.

Tape for posters will be provided. Posters can be posted from 12.00hrs on Saturday September 20th, and should be removed no later than 14.00hrs on Wednesday September 24th. The organizers cannot be held responsible for any posters left after this time.

All posters have been given a number and should be placed on the board marked with the same number.

Program Changes

The organizers cannot assume liability for any changes in the program due to external or unforseen circumstances.

Language

The official language of the Congress is English.

Badges

The Congress badges will be given to each participant by the Congress Secretariat. The badges are NECESSARY for the admission and entrance in Congress Halls and exhibition areas.

Congress Material

The Congress participants who have pre-registered will receive the Congress material, as well as their badge from the Pre-Registered Office of the Congress Secretariat.

CME

21 CME credits have already been proposed.

Coffee breaks and Lunches

Coffee breaks and lunches will take place at the Olympic Hall II as per the time scheduled indicated in the programme.

All registered participants will receive coffee break and lunch coupons from the Congress Secretariat with the congress material.

Invitation Letters

Persons requiring an invitation letter in order to attend the Congress may contact the Congress Secretariat. The procedure aims to facilitate participants' visa arrangements and should not be considered commitment by the Organizing Committee to provide funds for the participants attendance in the congress.

Attendance Certificates

Attendance Certificates will be given by the Congress Secretariat.

Credit Cards

All credit cards are acceptable in hotels, restaurants and shops.

Insurance

We cannot accept responsibility for any personal loss, accidents or damages to participants and/or accompanying persons. Participants are strongly advised to obtain personal insurance to cover any eventuality that may occur during the Congress.



Visa

Visa requirements may differ according to the country of origin. Please contact your travel agent or the Greek Consulate or Embassy in your country for further advice.

An official letter of invitation to attend the Conference can be forwarded to any participants upon request for use in obtaining a visa. However, this invitation implies no obligation, financial or otherwise, by ETA or Global Events.

Technical Equipment

The Congress Hall will be equipped with slide and data projectors as well as PC for speakers' needs. Speakers are kindly requested to use English language, check and deliver their presentation to the Technical Secretariat of the Congress, at least one hour prior to their scheduled presentation.

Internet Hot Spot

Internet point will be available to registered partisipants at Olympic Hall Foyer.

Climate

Greece has a warm Mediterranean climate. The month of September is hot with an average temperature of 20°-30° C. Rain is possible.

Special Needs

Delegates and accompanying persons with disabilities are kindly requested to contact the secretariat of the Congress, for any special requirements. The Congress's area is easily reached by persons with special needs.

Shuttle Bus Schedule

Friday, September 19th, 2008

From Makedonia Airport to Neos Marmaras Village and Porto Carras Grand Resort 11.00, 14.00, 16.00, 18.15, 22.45

Saturday, September 20th, 2008

From Makedonia Airport to Neos Marmaras Village and Porto Carras Grand Resort 06.00, 10.00, 14.00, 14.15, 15.45, 18.00, 21.00

From Neos Marmaras Village to Porto Carras Grand Resort: From Porto Carras Grand Resort to Neos Marmaras Village:	07.30 22.30, 23.00.23.30
Sunday, September 21st, 2008 From Neos Marmaras Village to Porto Carras Grand Resort: From Porto Carras Grand Resort to Neos Marmaras Village:	06.00 18.30
Monday, September 22nd, 2008 From Neos Marmaras Village to Porto Carras Grand Resort:	06.00
Tuesday, September 23rd, 2008 From Porto Carras Grand Resort and Neos Marmaras Village:	to Makedonia Airport 09.00, 12.00, 17.00
From Neos Marmaras Village to Porto Carras Grand Resort:	06.00
Wednesday, September 24th, 2008 From Porto Carras Grand Resort and Neos Marmaras Village:	to Makedonia Airport 05.00, 09.00, 11.00, 12.00, 13.30, 16.00
From Neos Marmaras Village to Porto Carras Grand Resort:	08.00

Timetable will be also displayed in hotel and at the Secretariat desk.



Travel Information

Thessaloniki Taxi Services

• RADIOTAXI MERCEDES

Accommodates both routes (Thessaloniki-Neos Marmaras, Neos Marmaras-Thessaloniki)

Contact Details: 2310 525000, 2310 556203, 2310 556204 Cost per route: approximately 100€ Time: approximately 1 ½ hours

Station operates 24 hours a day

• RADIOTAXI MAKEDONIA

Accommodates both routes (Thessaloniki-Neos Marmaras, Neos Marmaras-Thessaloniki)

Contact Details: 2310 550501 Cost per route: approximately 95€ Time: approximately 1 ½ hours

Station operates 24 hours a day

Chalkidiki Taxi Services

• RADIOTAXI SITHONIA

Accommodates both routes (Thessaloniki-Neos Marmaras, Neos Marmaras-Thessaloniki)

Contact Details: 23750 71500 Cost per route: approximately 95€ Time: approximately 1 ½ hours

Stations operates daily until midnight * For taxi appointments with this service, please contact them before midnight

Public Bus Services (Chalkidiki KTEL)

Accommodates both routes (Thessaloniki-Neos Marmaras, Neos Marmaras-Thessaloniki)

Contact Details: 2310-316555, 2310-316565 Email: helpdesk@in-ktel.gr Adress: Ktel Chalkididiki, Periohi Pilea, Thessaloniki

Bus station: outside the general entrance of Porto Carras

Cost per pax/per route: 11, 70€ Time: approximately 2 hours

KTEL Schedule Thessaloniki – Neos Marmaras 09:15, 12:45, 17:15

Neos Marmaras - Thessaloniki 06:00, 08:15, 12:30, 15:00, 18:30, 19:30



Boat Services

Accommodates routes from Neos Marmaras to Porto Carras and from Porto Carras to Neos Marmaras

Cost: 2.00€ per pax (children from 0-6 no charge) Time: approximately 10 minutes

Boat Schedule

Porto Carras – Neos Marmaras 10:00,11:00,12:00,13:00,14:00,15:00,17:00,18:00,19:00,20:00,21:00,22:00,23:00,23:45,00:15

Neos Marmaras – Porto Carras

10:30,11:30,12:30,13:30,14:30,16:30,17:30,18:30,19:30,20:30,21:30,22:30,23:30, 00:00

Important Note

Outside the airport you can find a taxi station, where you can pick-up a cab to reach Porto Carras Grand Resort and / or Neos Marmaras Village. However, since this transfer has not been arranged in advance, the cost is flexible. It is advisable to fix it in advance.



ACKNOWLEDGEMENTS

The Local Organising Committee wishes to thank the below-mentioned companies.





















PORTO CARRAS MAP





CHALKIDIKI MAP



PROGRAMME AT A GLANCE

	Saturday, September 20th, 2008	l	
08.30-16.00	ICCIDD West Central Europe Regional Satellite Meeting	OLYMPIC HALL I	
09.30-15.50	ETA-CRN The 8th meeting of the European Thyroid Association Cancer Research Network (ETA – CRN)	OLYMPIC HALL III	
8.30-16.00	Practical Diagnostic Thyroid and Parathyroid Ultrasonography Course	MELITON HOTEL - ERATO HALL	
17.30-19.00	Satellite Symposium Somatostatin analogs: Current and future therapeutic indications	OLYMPIC HALL I	
19.00-20.00	Opening Ceremony		
20.00-22.30	Welcome Reception		
	Sunday, September 21st, 2008		
06.45-07.15	Breakfast	MELITON & SITHONIA HOTEL	
07.15-08.30	Satellite Symposium (Genzyme Europe)	OLYMPIC HALL I	
	From guidelines to clinical practice: the practical management of thyroid cancer patients		
08.30-10.30	Topic Highlights I	OLYMPIC HALL I	
10.30-11.00	Coffee break	OLYMPIC HALL II	
11.00-12.30	Symposium 1 (Basic)	OLYMPIC HALL III	
11.00-12.30	Symposium 2 (Educational)	OLYMPIC HALL I	
12.30-12.45	Lunch Break	OLYMPIC HALL II	
12.45-14.00	Poster Discussion (P001 – P058)	OLYMPIC HALL II	
14.00-14.50	Special Lecture The Revolution in intercellular communication: Looking back and looking ahead	OLYMPIC HALL I	
15.00-15.45	Meet the Experts 1	MELITON HOTEL - ERATO HALL	
15.00-15.45	Meet the Experts 2	MELITON HOTEL - TERPSICHORI HALL	
15.00-15.45	Meet the Experts 3	OLYMPIC HALL I	
15.00-15.45	Meet the Experts 4		
15.45-16.00	Coffee Break		
16.00-18.00	Symposium 3 (Translational)		
16.00-18.00	Oral Session 1	OLYMPIC HALL III	
06 45 07 45	Monday, September 22 nd , 2008		
06.45-07.15	Breakfast	MELITON & SITHONIA HOTEL OLYMPIC HALL I	
J7.15-06.30	Satellite Symposium (Merck Serono) Clinical highlights in thyroidology		
08.30-10.30	Oral Session 2	OLYMPIC HALL I	
08.30-10.30	Oral Session 3	OLYMPIC HALL III	
10.30-11.00	Coffee break	OLYMPIC HALL II	
11.00-12.30	Symposium 4 (Educational)	OLYMPIC HALL I	
11.00-12.30	Symposium 5 (Translational)	OLYMPIC HALL III	
12.30-12.45	Lunch Break		
12.45-14.00	Poster Discussion (P059 – P119)	OLYMPIC HALL II OLYMPIC HALL I	
14.00-14.50	The European Thyroid Association Harington-De Visscher Prize Lecture	OLYMPIC HALL I	
15.00-15.45	Meet the Experts 5 Clinical Case Discussion - Subclinical Thyroid Disease		
16.00	Departure for the excursion		
10.00	Tuesday, September 23 rd , 2008		
06.45-07.15	Breakfast	OLYMPIC HALL I	
07.15-08.30	Satellite Symposium (Astra Zeneca) Taking aim: targeted therapies in medullary thyroid cancer	OLYMPIC HALL I	
08.30-10.30	Oral Session 4	OLYMPIC HALL I	
08.30-10.30	Oral Session 5	OLYMPIC HALL III	
10.30-11.00	Coffee Break	OLYMPIC HALL II	
11.00-12.30	Symposium 6 (Clinical)	OLYMPIC HALL II	
11.00-12.30	Symposium 7 (Basic)	OLYMPIC HALL I	
12.30-12.45	Lunch Break	OLYMPIC HALL II	
12.45-14.00	Poster Discussion (P120 – P191)	OLYMPIC HALL II	
14.00-14.50	The European Thyroid Association/Merck KGaA Prize	OLYMPIC HALL I	
15.00-15.45	Meet the Experts 6	MELITON HOTEL - ERATO HALL	
15.00-15.45	Meet the Experts 7	OLYMPIC HALL I	
15.00-15.45	Meet the Experts 8	OLYMPIC HALL II	
15.00-15.45	Meet the Experts 9	MELITON HOTEL - TERPSICHORI HALL	
15.45-16.00	Coffee Break	OLYMPIC HALL II	
16.00-17.15	Symposium 8	OLYMPIC HALL I	
16.00-17.15	Oral Session 6	OLYMPIC HALL III	
17.15-18.30	General Assembly	OLYMPIC HALL I	
19.00	Departure for Gala Dinner Wednesday, September 24 th , 2008		
8.30-10.30	Topic Highlights 2	OLYMPIC HALL I	
		OLYMPIC HALL II	
	Collee Dreak		
10.30-11.00	Coffee Break Symposium 9 (Clinical)	OLYMPIC HALL I	
10.30-11.00 11.00-12.45 11.00-12.45			

Taking aim targeted therapies in medullary thyroid cancer

Olympic Hall I, Porto Carras Grand Resort Sithonia, Chalkidiki, Greece Tuesday 23 September 7:15am-8:30am

(A buffet breakfast to be served from 7:00am-7:15am)

PROGRAMME

7:15 Introduction

Samuel Wells (Co-chair) Washington University School of Medicine, St Louis, USA

7:25 Targeting oncogenic pathways for medullary thyroid cancer therapy

Massimo Santoro Universitá di Napoli, Italy

7:45 Design and conduct of clinical trials for targeted agents in medullary thyroid cancer

Martin Schlumberger Institut Gustave Roussy, France

8:05 Clinical development of vandetanib in medullary thyroid cancer

Samuel Wells

8:25 Concluding remarks

Martin Schlumberger (Co-chair)



AstraZeneca Alderley House, Alderley Park Macclesfield, Cheshire, UK www.astrazeneca.com